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CHAPTER I 
 
 MANGANESE AND HUNTINGTON’S DISEASE 
 
Huntington’s disease (HD) is a neurodegenerative disorder with hyperkinetic symptoms due to loss of medium 
spiny neurons (MSNs) in the caudate and putamen of the striatum. HD is caused by a polyglutamine tract 
expansion with longer expansions leading to earlier age at onset. However, environmental modifiers have been 
shown to play a large role in age of onset variability. Decreased manganese levels in HD cell and mouse 
models as well as patient brains illustrate a potential role for manganese as an environmental modifier. 
Strikingly, many HD-related phenotypes involve manganese-dependent enzymes; thus, dysregulated 
manganese homeostasis could underlie key aspects on HD pathophysiology. Additionally, manganese and 
mutant Huntingtin affect similar cellular signaling events. Although the decreased manganese accumulation in 
the mouse models of HD was intriguing, we wanted to investigate these findings in a human neuronal system, 
which has only recently become possible. Induced pluripotent stem cells (iPSCs) can be generated from a 
patient’s dermal cells and can be subsequently differentiated into neuronal cells. Medium spiny neurons, the 
cells selectively degenerated in HD, have been directly differentiated from human iPS and ES cells. 
 
Huntington’s disease 
Huntington’s disease (HD) is a devastating neurodegenerative disease presenting with impaired movement, 
psychological and behavioral disturbances, and cognitive decline. The most pronounced symptoms are motor 
impairments including chorea, motor impersistence, and deterioration of coordination and motor skills (Walker, 
2007). Typically, chorea, a hyper-kinetic “dance-like” symptom, presents around diagnosis and was the chief 
characteristic used by George Huntingtin to first describe the disease in 1872 (Huntington, 2003). In late stage 
HD - or earlier in the juvenile onset form - these hyper-kinetic symptoms give way to hypo-kinesis and rigidity 
similar to patients with Parkinson’s disease (Zuccato et al., 2010). HD typically results in death in the second 
decade after the time of clinical diagnosis, often from cardiovascular disease or complications such as falls, 
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difficulty swallowing, aspiration leading to pneumonia, and an increased suicide rate (Folstein, 1989).The motor 
symptoms are thought to primarily result from neuronal degeneration in the caudate and putamen regions of 
the basal ganglia. The GABAergic medium spiny neurons in these regions are the most susceptible to HD-
related degeneration (Gutekunst et al., 2002); however, neurons in the substantia nigra, globus pallidus, 
thalamus, subthalamic nucleus, subregions of the hypothalamus, and cortical layers 3, 5, and 6 are also 
vulnerable to cell death in HD (Walker, 2007; Zuccato et al., 2010). More recent MRI studies have found 
varying degrees of degeneration in nearly all brain regions in early disease (H D Rosas et al., 2003). Currently, 
no treatments have been proven effective for HD patients, and the specific mechanism underlying the selective 
degeneration is undetermined.  
Huntington’s disease (HD) is a dominantly inherited genetic disorder and affects approximately 6 
persons per 100,000 (P. Kumar et al., 2010). In 1993, the genetic cause of the disease was identified in the 
gene now known as Huntingtin (HTT). In Huntington’s disease patients, a CAG repeat region (typically 20 
repeats) in HTT expands within the coding region of the Huntingtin gene (HTT) (MacDonald et al., 1993). HD 
can occur in individuals with repeat lengths greater than 35 glutamine codons (CAG). Individuals with 36-39 
repeats show incomplete penetrance and those with >70 repeats typically display HD symptoms in childhood 
(David C Rubinsztein et al., 1996). However, one study reported a patient with a post-mortem diagnosis of HD 
had a repeat length of 29 on the longer allele (Kenney et al., 2007). 
 
Environmental influence in Huntington’s disease 
Genetic factors determine a large portion of the variability in HD onset and progression; however, 
environmental factors also play a substantial role in disease modification. HD age of onset (AO) can occur from 
2 to >80 years of age. More than half of this variability is determined by the length of the CAG repeat with 
longer repeats resulting in earlier onset (Andrew et al., 1993; Langbehn et al., 2004). The remaining variability 
is determined by other genetic and environmental disease modifiers. The environment was found to play the 
most significant role in this non-repeat dependent disease variability in one landmark study (Wexler, 2004). 
This environmental modifier contribution to age of onset is thought to increase with shorter repeat lengths. In 
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fact, patients with a repeat length of 40 can have ages of onset spanning four decades (Wexler, 2004). Even 
monozygotic twins with HD have shown differences in symptomatic manifestations and age of onset (up to 7 
years) (Anca et al., 2004; Friedman et al., 2005; Georgiou et al., 1999; Gomez-Esteban et al., 2006). 
Therefore, environmental exposures play a role in HD disease progression but few specific environmental 
modifiers have been identified (Hockly et al., 2002; Spires et al., 2004; van Dellen et al., 2000).  
Thus far, non-genetic influences such as environmental enrichment, exercise, and diet interventions 
have been shown to delay disease progression (Andreassen, Dedeoglu, et al., 2001; Andreassen, Ferrante, 
Dedeoglu, & Beal, 2001; Wenzhen Duan et al., 2003; Ferrante et al., 2000; Hockly et al., 2002; Pang et al., 
2006; Spires et al., 2004; van Dellen et al., 2000). Rodent environmental enrichment includes access to 
running wheel and novel object, and this exposure decreases disease severity in transgenic HD mouse models 
(Nithianantharajah & Hannan, 2006). Reduced production and trafficking of brain-derived neurotrophic factor 
(BDNF) is a major phenotype of HD, and enrichment has been linked to increases in BDNF expression (Glass 
et al., 2004; Zajac et al., 2010; Zuccato & Cattaneo, 2007). Dietary restriction has also been shown to increase 
mouse BDNF levels and thereby normalizes the BDNF levels of HD mice decreasing disease severity and 
increasing lifespan 30. Essential fatty acid supplementation can also prevent some motor deficits in an HD 
mouse model (Clifford et al., 2002; W Duan et al., 2001). In addition to these protective effects of the 
environment, many environmental compounds can synergistically increase the progression of 
neurodegeneration. In some neurodegenerative diseases, such as Parkinson’s disease (PD), environmental 
toxins are thought to be a primary causative agent (Turski et al., 1991).  Other factors which may accelerate 
the pace of HD are those that cause oxidative stress and mitochondrial damage such as heavy metals and 
pollutants, which are known to cause degeneration of basal ganglia subregions (Betarbet et al., 2000; 
Bowman, Kwakye, Herrero Hern√°ndez, et al., 2011; Jomova et al., 2010). Although it has been more than 
twenty years since the Huntingtin gene was identified, it has been difficult to identify environmental disease 
modifiers because the function of the ubiquitous Huntingtin protein throughout development is still only partially 
understood. 
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Huntingtin has many diverse functions, and for this reason, the mutant form leads to many diverse 
cellular pathologies including calcium signaling abnormalities, mitochondrial dysfunction, neurotrophic factor 
reduction, excitotoxicity, transcriptional dysregulation, protein aggregate formation, and altered autophagy 
(Damiano et al., 2010; Martinez-Vicente et al., 2010; Zeron et al., 2002; H. Zhang et al., 2008; Zuccato & 
Cattaneo, 2007; Zuccato et al., 2010). Knockout of the Huntingtin gene is embryonically lethal in mouse 
models (Duyao et al., 1995; Nasir et al., 1995; Zeitlin et al., 1995). Additionally, partial knockdown of Huntingtin 
leads to neurodevelopmental abnormalities in both zebrafish and mice (Lumsden et al., 2007; White et al., 
1997). Mutant Huntingtin is able to rescue both of these phenotypes, suggesting that neurodegeneration in HD 
results from a toxic gain of function rather than a of loss of wild-type Huntingtin function (White et al., 1997). 
Interestingly, Hungtingtin is understood to be expressed in all tissues of the body at all developmental time 
points, and considering the late onset of neurodegeneration (typically between 30 and 50 years of age) may 
indicate that mutant Huntingtin expression is not sufficient to cause pathology but requires normal age-related 
environmental stress (D C Rubinsztein et al., 1997; Stine et al., 1995; White et al., 1997; Woda et al., 2005). 
This potential environmental role in Huntington’s disease opens up the possibility of delaying onset by avoiding 
potential toxic exposures or by enriching environments and increasing nutritional protection and thereby 
altering the impact of age-related environmental stress. Furthermore, the identification of specific pollutants or 
heavy metals, which may serve as environmental modifiers, could lead to potential targets for pharmaceutical 
intervention to delay the onset of Huntington’s disease symptoms. 
 
Huntington’s disease and metal ions 
Heavy metals are closely linked with both function and dysfunction in the basal ganglia, and are, therefore, 
likely candidates to be the environmental modifiers for age of onset in HD (Bowman, Kwakye, Herrero 
Hern√°ndez, et al., 2011). The high metabolic requirements of the brain as well as the need for tight regulation 
and detoxification of reactive oxygen species necessitates high concentrations of micronutritive heavy metal 
ions (i.e. Fe2+, Mn2+, Cu2+, and Zn2+) that are important cofactors for enzymes that regulate these processes. 
On the other hand, excessive metal ion concentrations result in increased oxidative stress, mitochondrial 
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dysfunction, protein aggregation, and apoptosis. For this reason, heavy metal toxicity and neurodegeneration 
have many shared mechanisms and symptomatic features (Gaeta & Hider, 2005; Jomova et al., 2010; Molina-
Holgado et al., 2007). Excess accumulation of heavy metals in the brain either from exposure (e.g. 
manganism) or via genetic disturbance of metal ion homeostasis (e.g. Wilson’s disease) can lead to 
degeneration of brain regions, particularly in the basal ganglia (Ala et al., 2007; Dobson et al., 2004). 
Abnormally low concentrations of micronutritive metals in the brain are also detrimental to brain development 
and function (Beard, 2003; Dipaolo et al., 1974; Erway et al., 1970; Keen et al., 1998; Walter et al., 1989; 
Zidenberg-Cherr et al., 1983). The similarities in pathobiology between neurodegeneration and metal toxicity or 
deficiency, warrants further investigation into shared mechanisms. Because manganism and Huntington’s 
disease overlap in symptomology, a derangement in manganese exposure or handling may explain some of 
the variation in timing of disease onset, as well as some of the function of the Huntingtin protein in brain. 
 
Manganese and HD 
Few studies have measured the level of manganese in the brains of HD patients. Dexter et al (1991) did not 
find any differences in manganese levels, but a more recent study, Rosas et al (2012), found a significant 
decrease in manganese concentration in parts of HD cortex (Dexter et al., 1991; H Diana Rosas et al., 2012). 
Additionally, increased iron accumulation in the striatum and pallidum of HD patients has been seen in multiple 
studies (Bartzokis et al., 1999; Dexter et al., 1991; H Diana Rosas et al., 2012), and manganese has a strong 
inverse correlation to iron concentration in the basal ganglia (Erikson et al., 2004). Therefore, increased iron 
accumulation could result in a slight reduction in manganese levels in Huntington’s disease striatum beyond 
the detection of the previous studies. Manganese is known to accumulate in the globus pallidus and caudate 
nucleus, two areas highly susceptible to HD neurodegeneration (Larsen et al., 1979; Prohaska, 1987). This 
accumulation may highlight a specific necessity of manganese for proper function, and may also make these 
brain areas more susceptible to fluctuations in manganese levels. 
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Recently, an immortalized striatal murine Huntington’s disease model cell line (STHdhQ7/Q7 and 
STHdhQ111/Q111) showed differential toxicological sensitivity to manganese (Mn2+) and cadmium (Cd2+) but no 
other metal ions tested (Fe3+, Cu2+, Pb2+, Co2+, Zn2+, Ni2+) (Williams, Kwakye, et al., 2010). Mutant Huntingtin 
expression conferred a survival advantage under manganese exposure conditions in these cells due to a 
dramatic decrease in manganese uptake (Williams, Kwakye, et al., 2010). This differential manganese level 
was also observable under basal conditions despite the extremely low concentration of manganese in normal 
cell culture conditions.(Williams, Kwakye, et al., 2010) Expression of human mutant Huntingtin also caused a 
decrease in manganese levels in the brains of manganese-exposed mice (Williams, Kwakye, et al., 2010). 
Interestingly, this difference was seen only in the mouse striatum, the specific region that degenerates in the 
brains of Huntington’s disease patients, and not the cerebellum, cortex, or hippocampus, which are largely 
spared early in disease progression. The proximal cause for this alteration in manganese homeostasis is 
currently under investigation; however, the possibility of a manganese-handling defect in Huntington’s disease 
will be further explored in this chapter. 
Glia make up 50% of total brain tissue and >75% of the cerebral cortex (Azevedo et al., 2009). These 
cells are reported to contain ~80% of total brain manganese, and gliosis is a known manifestation of HD 
(Filipov & Dodd, 2012; Tholey et al., 1988; F. Wedler & Denman, 1984). A more dramatic deficit in the amount 
of manganese in HD patient neurons could, therefore, exist despite relatively small differences in overall 
cortical manganese and no observable differences in manganese in the basal ganglia, when measured without 
regard to cell type (Dexter et al., 1991; H Diana Rosas et al., 2012). The in vivo striatal differences revealed in 
the HD mice were seen using a manganese over-exposure paradigm but not under basal conditions (Williams, 
Kwakye, et al., 2010). Therefore, the human HD caudate and putamen may have a cell-type specific 
manganese defect that would only become apparent with over exposure. To address a cell-type specific 
defect, ex vivo primary cell culture of both medium spiny neurons and astrocytes from the HD mouse striatum 
are warranted. 
In addition to the differences in manganese accumulation, manganese exposure exacerbated 
abnormalities in dendritic complexity and arborization seen in the medium spiny neurons of YAC128 HD model 
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mice, which contain a mutant human HTT gene containing 128 CAG repeats (Madison et al., 2012). In this 
same in vivo model, curiously, the HD genotype suppressed the Mn-dependent decrease in striatal dopamine 
levels(Madison et al., 2012). Therefore, HD brains may have manganese deficits that can endanger processes 
requiring manganese as a cofactor, while also being more susceptible to some aspects of manganese toxicity. 
These studies into the interactions between manganese and HD have produced useful insights into the 
potential altered regulation of manganese homeostasis; however, the full range of potential reasons for the 
underlying disease-toxicant interaction has not yet been explored. The breadth of HD-related cellular 
phenotypes is diverse and multi-factorial (Ross et al., 2014; Zuccato et al., 2010). For this reason, a clear 
hypothesis connecting the similarities in manganese and HD pathology is needed. Section 3 of this chapter will 
outline numerous HD-related phenotypes that may have relevance to manganese biology.  Within each 
section, HD-associated manganese-containing enzymes and similarities in manganese deficiency and/or 
toxicity to HD pathology will be highlighted because of the critical balance of this metal.  
 
Iron and HD 
In addition to abnormalities in manganese homeostasis, Huntington’s disease has also been associated with 
abnormal iron homeostasis. HD patients have increased accumulation of iron in the caudate, putamen, and 
pallidum (Bartzokis et al., 1999; Dexter et al., 1991; H Diana Rosas et al., 2012). In the same studies, ferritin 
levels were unchanged between HD patients and control subjects in all of the brain regions examined; 
however, other authors have found increased ferritin levels in striatum and cortex of HD brains, with staining 
primarily in microglia (J. Chen et al., 1993; Simmons et al., 2007). Neuroferritinopathy, a condition caused by 
mutation in the ferritin light chain gene (FTL1), results in accumulation of iron and ferritin in the basal ganglia 
(Levi et al., 2005). Neuroferritinopathy is associated with low serum ferritin levels, accumulation of iron and 
ferritin in the basal ganglia, oxidative stress, and signs of mitochondrial dysfunction, which are all seen in HD 
(Bonilla et al., 1991; Curtis et al., 2001). Neuroferritinopathy results in neurodegeneration in the basal ganglia 
as well as other symptomology similar to HD, and patients are often misdiagnosed as having Huntington’s 
disease (Chinnery et al., 2007; Curtis et al., 2001). Several studies have also linked wild-type Huntingtin 
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protein function directly to iron homeostasis. Partial knockdown of Huntingtin in a zebrafish embryo model 
resulted in a lack of bioavailable iron for hemoglobin in red blood cells despite adequate levels of total iron in 
the cells. Therefore, Huntingtin may be needed for iron release from endocytic vesicles (Lumsden et al., 2007). 
Increasing the morpholino concentration to knock-down more Huntingtin in this fish model resulted in a 
dramatic effect on overall CNS development with reduced size of brain and eye, and brain necrosis, which may 
or may not be linked to iron availability (Lumsden et al., 2007). 
This close link between iron homeostasis and Huntington’s disease suggested that an iron trafficking 
defect could have caused the altered manganese concentration in striatal neurons seen in Williams et al 2010 
(Williams, Kwakye, et al., 2010). A shared defect seems likely because many iron transport processes (e.g. 
transferrin, DMT1) also traffic manganese ions (Roth, 2006). Iron transporters were assessed in the cultured 
striatal lines, and the transferrin receptor was found to be significantly lower (less than 50%) in the mutant cells 
compared to wild type (Williams, Kwakye, et al., 2010). High concentrations of iron were then used to saturate 
iron-dependent transporters, which partially blocked manganese uptake. This paradigm diminished Mn-
dependent cell death in both cell lines equally, suggesting that iron transporters, such as the transferrin 
receptor, do account for a portion of manganese uptake in the mouse striatal cells but do not account for 
altered manganese accumulation in HD cells. Accumulation of iron (Fe3+) in the mutant cells was also lower in 
HD cells; however, the fold change was much less than that of manganese and seemed to correlate with the 
difference in transferrin receptor expression. Unlike manganese levels, iron levels were the same in both cell 
lines when they were not exposed to excess iron (Williams, Kwakye, et al., 2010). 
In addition to the need for bioavailable iron for many key cellular processes, excess iron and/or copper 
can increase oxygen free radicals via Fenton chemistry. In this process, a metal ion cycles between redox 
state II and III by disproportionate cleavage of a hydrogen peroxide molecule resulting in the formation of water 
and a highly reactive free radical (either HO! or HOO!) (Wardman & Candeias, 1996). These reactive oxygen 
species (ROS) can then cause DNA damage and both protein and lipid peroxidation, processes that cause 
cellular dysfunction and activate necrotic and apoptotic events. Huntington’s disease models demonstrate 
higher levels of (ROS) and increased sensitivity to ROS mediated damage (Browne et al., 1999). Derangement 
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of metal ion uptake and transport may partially contribute to the neurodegeneration seen in Huntington’s 
disease through this iron-related formation of ROS, along with damage caused by imbalances in other metal 
ions such as manganese and copper.  
 
Copper and HD 
In addition to iron, copper was also found to be increased in the brains of HD patients in some studies but not 
others (Dexter et al., 1991; H Diana Rosas et al., 2012). Accumulations were seen in the striatum and cortex of 
R6/2 HD model mice (Fox et al., 2007). Expression of mutant exon1 of the Huntingtin gene in yeast led to 
increased expression of eight copper binding proteins including metallothionein 1 and 2 (MT1 and MT2) 
(Hands et al., 2010). These two genes also showed increased mRNA expression in HD patient brains (Hodges 
et al., 2006). Copper has been shown to facilitate mutant Huntingtin aggregation (Fox et al., 2007). Mutant 
Huntingtin is known to cause inclusions via aggregation in the nucleus and cytoplasm (Davies et al., 1997). 
These aggregates were thought to be important mediators of HD pathology; however, recent studies have 
shown a lack of direct connection between cell death and aggregates, indicating a potentially protective effect 
of aggregation (Bjokoy et al., 2005). 
Despite this potentially positive role of copper in inducing mutant aggregation, reduction of copper via 
chelation or via genetically knocking-down copper transporters has mitigated HD pathology in both mouse and 
fly models of HD while simultaneously reducing aggregation (Nguyen et al., 2005; G. Xiao et al., 2013). Copper 
treatment also further decreased the lifespan of HD flies (G. Xiao et al., 2013). These models, however, 
express only exon1 of the mutant gene, and aggregation may be a necessary step in pathology with these 
imperfect model systems. Therefore, copper may play a different (or no) role in patients and animals 
expressing the full-length mutant Huntingtin gene. Alternatively, Boll et al 2008 showed decreased activity of 
Cu/Zn SOD in HD patients with a trend for increased free copper in the patient CSF (Boll et al., 2008). Since 
free copper is a Fenton reagent leading to increased ROS production, copper may add to HD pathology in this 
way. The alterations in iron, copper, and manganese seen in HD patients and in HD model organisms 
	   10	  
suggests that metal-handling may be one of the functions of the Huntingtin protein affected by expansion of the 
pathogenic polyglutamine domain.  
 
Manganese essentiality and toxicity in HD related phenotypes 
As discussed above, HD patients and mouse in vivo and in vitro models exhibit decreased manganese levels 
either upon basal and/or elevated exposure to manganese (Section X.2.1). Manganese deficiency results in 
many dysfunctional manifestations similar to Huntington’s disease including: urea cycle dysfunction, altered 
glutamate regulation, increased oxidative stress, and metabolic disturbances including altered IGF-AKT 
signaling. The following subsections will investigate the interrelationship between these manganese-dependent 
processes and HD-related pathological phenotypes highlighting enzymes in each process that use manganese 
as a cofactor. 
 
Regulation of amines and nitric oxide  
Nitrogen is one of the most important elements in biological systems. Amino acids, protein monomers, all 
contain one amine group containing nitrogen, and many contain an additional amine on their R-subunit (i.e. 
asparigine, arginine, glutamine, and lysine). During normal cellular biochemical processes, deamination 
releases ammonia into the cytoplasm and eventually the blood stream, but elevated ammonia levels are toxic 
and can lead to encephalopathy and death. To regulate ammonia levels, the liver produces urea to be excreted 
into urine to deplete the human body of excess amines. Arginine is an important precursor in the urea cycle as 
well as an additional process called the nitric oxide cycle. Nitric oxide (NO) is a compound produced from 
arginine via nitric oxide synthase (NOS). NO regulates many important functions and in the CNS it acts as a 
neurotransmitter and neuromodulator, particularly regulating glutamate release in the cortex, striatum, and 
hippocampus. Although its production is vital to many biological functions, excess NO can be neurotoxic via 
glutamate excitotoxicity and oxidative stress (Calabrese et al., 2007; Dawson et al., 1991). Increased arginine 
levels can activate NOS activity increasing NO signaling (Durante et al., 2007). Therefore, although the liver is 
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the primary producer of excreted urea, the brain also converts arginine to ornithine and urea to regulate the 
production of NO.  
Arginase is a manganese-dependent enzyme that catalyzes the conversion of arginine to ornithine. 
Arginase contains a binuclear manganese cluster of six Mn ions that is vital for its function and cannot be 
substituted with magnesium like many other manganese containing enzymes (Kanyo et al., 1996). Dietary 
manganese deficiency decreases arginase activity and increases NOS activity (Brock et al., 1994; Ensunsa et 
al., 2004). Two genes (ARG1 and ARG2) encode for the two isozymes, ARG1 and ARG2. These two enzymes 
have identical enzymatic function, but ARG1 is primarily in the cytoplasm whereas ARG2 is located in the 
mitochondria. ARG1 has been found at higher levels in the brain than ARG2 (Yu et al., 2001). ARG2 
expression is especially high in particular areas of the brain affected by HD, including the putamen and ventral 
striatum (Braissant et al., 1999). 
Evidence of altered arginase activity has been reported in both mouse models of HD and peripheral 
measures from HD patients. At least two different HD model mice (the "R6/2" and a Hdh knock-in model have 
shown increased ammonia and citrulline levels, both indicative of decreased arginase activity (Chiang et al., 
2007; Pouladi et al., 2013). Similarly, HD patients were shown to have increased blood citrulline levels 
indicating increased NOS activity (Chiang et al., 2007). Arginase transcript levels were also found to be 
reduced in HD mouse liver (Chiang et al., 2009). Other groups using a non-neuronal cell model showed 
increase ARG1 expression, NOS and arginase activity in HD mutant cells that correlated with an increase in 
arginine uptake (Colton et al., 2004). Dysregulation of arginase by altered manganese 
homeostasis/bioavailability could result in localized ammonia and NO-related toxic processes as well as 
altered production of glutamate and GABA which require the conversion of ornithine from arginine as a 
precursor for their production (Shank, 1983). These HD phenotypes could be the result of altered bioavailability 
of manganese as has been seen in manganese exposed mouse striatal cells and striatal tissues (Williams, 
Kwakye, et al., 2010). 
Knockdown of neuronal NOS in the R6/1 mouse model of HD delayed disease symptoms and 
increased dietary arginine accelerated symptom onset by increasing NO synthesis (Deckel, 2001; Deckel et al., 
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2002). This interaction between NO level and HD pathology may be due to the necessity of NO in a process 
called glutamate excitotoxicity, a well-studied HD pathological phenotype (Dawson et al., 1991). Excessive NO 
can also interact with superoxide radicals to form more reactive oxygen species (ROS) as well as toxic reactive 
nitrogen species (RNS) that can cause severe cellular dysfunction. Increased oxidative stress due to reactive 
oxygen and nitrogen species (ROS and RNS) has been reported for several HD model systems (Browne & 
Beal, 2006; Browne et al., 1999).  Increased nitrates and nitrites, which are downstream products of NO 
signaling, are found in the cerebrospinal fluid of HD patients (Boll et al., 2008). Arginase 1 regulation of nitric 
oxide production has been shown to be a key to survival of trophic factor-deprived motor neurons (Estevez et 
al., 2006). Thus, altered arginase activity via altered manganese homeostasis in HD could potentially 
contribute to a wide range of HD-related phenotypes. 
Arginase activity increases polyamine synthesis downstream of the arginase reaction causing beneficial 
effects. Reduced arginase activity seen in HD models could also lead to dysfunction by reduced production of 
these polyamines. The production of spermidine in particular has been found to be neuroprotective and 
actually promotes axonal regeneration (Deng et al., 2009). Spermidine is a scavenger of reactive oxygen 
species and may therefore be protective against HD pathological processes (Ha et al., 1998). Spermine can 
rescue HD-related memory deficits in a rodent model (Velloso et al., 2009). One study found that spermine 
increased the rate of aggregate formation in a poly-Q cell model with increased cell death;(Colton et al., 2004) 
however, as previously mentioned, aggregation is no longer thought to be a part of the disease process and 
may actually be protective against mutant Huntingtin pathogenesis (Bjokoy et al., 2005; Slow et al., 2005). In 
fact, this may be a part of the protective nature of spermine in Huntington’s disease. 
 
Glutamate excitotoxicity  
Glutamate excitotoxicity is a well-supported pathophysiological process in Huntington’s disease (Behrens et al., 
2002; Zeron et al., 2002). This neurotoxic mechanism involves excessive glutamate-induced intracellular 
calcium release resulting in mitochondrial dysfunction. Figure 1 illustrates potential steps of glutamate cycling 
and signaling, the first steps of excitotoxicity, which manganese may impinge. There is no consensus yet about 
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how mutant Huntingtin leads to elevated exictotoxicity.  This section will outline several steps in the process 
from glutamate release to mitochondrial dysfunction and identify points in the process where either manganese 
and/or mutant Huntingtin may play a role in this pathophysiological process.  
Glutamate is the primary excitatory neurotransmitter of the CNS. In the caudate and putamen, a large 
component of excitatory tone comes from glutamatergic cortical presynaptic axon terminals synapsing with 
dendrites of the medium spiny neurons. Glutamate then binds to AMPA and NMDA glutamate receptors to 
cause membrane depolarization. NMDA receptors are permeable to Ca2+ in addition to Na+ and K+. This influx 
of calcium during depolarization is important for long-term potentiation and memory formation. Excessive 
glutamate released at the synapse can result in abnormal Ca2+ influx.  
To maintain efficient neurotransmission glutamate must be efficiently cleared from the synapse after 
release. Astrocytes typically account for 80% of synaptic glutamate uptake (Fitsanakis et al., 2006). 
Manganese decreases astrocytic glutamate uptake and decreases GLAST (astrocytic glutamate transporter) 
expression (Erikson & Aschner, 2003; Normandin & Hazell, 2002). Manganese can also increase synaptic 
glutamate release and inhibit NMDA receptors conductance as a channel blocker (Crooks et al., 2007; Guilarte 
& Chen, 2007). 
Huntington’s disease models have shown reductions in protein and mRNA of another astrocytic 
glutamate transporter, GLT1, as well as reductions in astrocytic glutamate uptake (Behrens et al., 2002; 
Lievens et al., 2001). As already discussed, the manganese-dependent enzyme arginase can also play a role 
in glutamate release by regulating ornithine production, a precursor to glutamate.   In addition to contributing to 
glutamate release and clearance, manganese also regulates glutamate levels through the process of 
converting of glutamate to glutamine. 
Glutamate that is taken up by astrocytes is converted into glutamine by glutamine synthetase within the 
glial cell. Glutamine can then be exported from the astrocyte for reuptake by the presynaptic neuron for 
conversion back into glutamate to help maintain neurotransmitter levels. Glutamine synthetase is the most 
abundant manganese-containing enzyme in the brain and is primarily expressed in glia (F. C. Wedler et al., 
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1982). Like arginase, glutamine synthetase has a high specificity for manganese over magnesium (F. C. 
Wedler & Ley, 1994). 
 
 
Figure 1. Effects of manganese and mutant Huntingtin on glutamate signaling and cycling at the corticostriatal 
synapse.  A cortical projection neuron (presynaptic) is synaptically joined to the dendrite of a medium spiny neuron in the 
striatum (postsynaptic). Upon depolarization, glutamate is released from the presynaptic terminal where it interacts with 
glutamate receptors such as the NDMA receptor. This receptor is calcium permeable and is important for calcium 
signaling but excess glutamate can cause excess calcium influx leading to excitotoxicity. Manganese is a known inhibitor 
of the NMDA receptor. Glutamate is cleared from the synapse by supporting astrocytes through glutamate transporters, 
GLAST and GLT-1, whose expression is known to be inhibited by manganese and mutant Huntingtin (mHTT) respectively. 
Glutamate is converted to glutamine in the astrocyte by glutamine synthetase, a manganese-dependent enzyme. 
Glutamine is released from the astrocyte to be taken back up in the presynaptic terminal. It is then converted back into 
glutamate via transglutaminase releasing ammonia. The glutamate is then repackaged into vesicles by a VGlut 
transporter. Illustrated by Angela Tidball. 
 
Loss of glutamine synthetase function by genetic mutation or inhibition of gene expression can lead to 
epileptic seizures (Thomas Eid et al., 2004; Häberle et al., 2005). These seizures are the result of glutamate-
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glutamine cycle dysregulation leading to excess extracellular glutamate (Tore Eid et al., 2008). Elevated risk for 
seizures occurs in HD, and post mortem brains of HD patients show a significant decrease in glutamine 
synthetase activity in the caudate and putamen compared to matched controls (Butterworth, 1986; Carter, 
1982). Mouse models have shown reductions in glutamine synthetase mRNA levels as well as activity 
(Behrens et al., 2002; Lievens et al., 2001). Additionally, patients with juvenile onset Huntington’s disease have 
even further increased risk of seizures with ~25% of patients presenting (Gambardella et al., 2001; Nance & 
Myers, 2001). A manganese-handling defect in isolated brain regions could potentially be reflected in reduced 
glutamine synthetase activity in HD although this direct relationship has not yet been explored. 
Manganese deficiencies alone are related to an increased seizure rate in both rats and humans 
(Dupont & Tanaka, 1985; Hurley et al., 1963; Papavasiliou et al., 1979). Since glutamate is the most abundant 
compound in the brain, cycling between glutamate and glutamine requires a high enzymatic output via 
glutamine synthetase and transglutaminase (Birken & Oldendorf, 1989). Manganese deficiency is proposed to 
decrease glutamine synthetase activity resulting in increased extracellular glutamate, which increases the 
propensity for seizures.  
The production of glutamine from glutamate also uses a free ammonia molecule. Increased ammonia 
levels in hyperammonemia have been known to increase the rate of glutamine production potentially buffering 
the brain from toxic levels of ammonia (Cooper, 2001). Reductions in hepatic glutamine synthetase have also 
been associated with hyperammonemia (Tuchman et al., 1997). Therefore, altered action of glutamine 
synthetase in Huntington’s disease and manganese deficiency could result in localized dysregulation of 
ammonia levels.  Manganese is clearly a crucial player in neuronal energetics as well as intercellular 
detoxification processes. 
 
Calcium dysregulation 
Calcium is tightly regulated in neurons.  As mentioned above, excess glutamate increases calcium influx 
through NMDA receptors.  NMDA and voltage-gated calcium channels allow calcium into the post-synaptic 
neuron during glutamate mediated membrane depolarization. In addition, metabotropic glutamate receptors 
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can cause calcium release from the endoplasmic reticulum via the inositol 1,4,5-triphosphate (IP3) pathway.  
These processes are vital for long-term potentiation and memory formation but can cause damage in excess. 
Medium spiny neurons containing mutant Huntingtin have been found to have abnormally high calcium release 
when exposed to the same concentration of glutamate (Tang et al., 2005). In addition to alterations in 
glutamate processing in HD which may lead to excess Ca2+ influx, mutant Huntingtin has been found to cause 
calcium dysregulation by binding to the IP3 receptor (IP3R) resulting in constitutive release of calcium from the 
smooth endoplasmic reticulum (SER) (Tang et al., 2005).  Mutant Huntingtin may also cause the ryanodine 
receptor to leak calcium from the SER (M. Suzuki et al., 2012). Cytoplasmic calcium is buffered by 
mitochondria; however, when calcium becomes excessively high, overwhelmed mitochondria can swell, 
depolarize, and open the mitochondrial membrane transition pore leading to apoptosis (Brustovetsky et al., 
2002). Interestingly, along with excess calcium, excess manganese also accumulates in the mitochondria 
where it can lead to dysfunction and depolarization.   
Many studies have used manganese as a calcium surrogate because it can easily be traced by MRI 
and radioactivity apart from the complexities of internally stored calcium (Koretsky & Silva, 2004). Manganese 
homeostasis is thought to rely heavily on calcium transporters. Huntington’s disease alterations in calcium 
homeostasis may alter shared calcium/manganese transporters, and, thus, underlie the HD-dependent 
manganese accumulation phenotype.  
 
Mitochondrial dysfunction: oxidative stress and energetics 
Mitochondrial stress can be caused by both excess calcium as well as excess manganese (Figure 2). 
Manganese and calcium are taken up by the mitochondrial calcium uniporter, and manganese is released very 
slowly by the Na(+)-independent efflux process (Gavin et al., 1998). These slow release kinetics help to buffer 
the cytosol from potentially toxic effects of these divalent cations; however, when the mitochondria become 
overloaded with either manganese or calcium, the imbalance can lead to impaired adenosine triphosphate 
(ATP) synthesis, membrane depolarization, uncoupling of the electron transport chain, and production of 
reactive oxygen species (Peng & Greenamyre, 1998). Manganese toxicity is known to inhibit all four 
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mitochondrial complexes of the electron transport chain via oxidative stress (S. Zhang et al., 2004). In isolated 
mitochondria, significant complex inhibition was achieved by 50 µM manganese that was blocked by several 
antioxidants indicating that oxidative stress is a major pathway of manganese inhibition of mitochondrial 
complexes (S. Zhang et al., 2004). Additionally, manganese toxicity inhibits the release of calcium from the 
mitochondria leading to a potentially toxic buildup (Gavin et al., 1998). In addition to mitochondrial toxicity due 
to excess manganese, reduced manganese levels are also harmful, altering the activity of the protective 
manganese super oxide dismutase, which also leaves mitochondria vulnerable to damage (Figure 2). Striatal 
 
Figure 2. Effects of manganese and mutant Huntingtin on calcium signaling and mitochondrial function. Models 
of HD have excess glutamate release at the synapse that can cause excessive influx of calcium into the cell from NMDA 
receptors. Mutant huntingtin (mHTT) has also been shown to cause leaking of the InsP3receptor causing dysregulated 
release of calcium from the endoplasmic reticulum. Excess calcium is buffered by the mitochondria where it is taken up by 
the mitochondrial calcium uniporter (MCU); however, in excess, calcium can cause mitochondrial swelling, depolarization, 
and opening of the mitochondrial permeability transition pore (mitoPTP) leading to apoptosis. In the same way, excess 
manganese is buffered in the mitochondria and can lead cell death in a similar mechanism. Additionally, manganese 
exposure has recently been shown to activate p53, which accelerates apoptosis by inhibiting manganese super oxide 
dismutase, a manganese-dependent free radical scavenger and by potentiating the opening of the mitoPTP. Illustrated by 
Angela Tidball. 
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neurons are particularly sensitive to glutamate-mediated excitotoxic cell death. This apoptotic event is 
dependent on elevated mitochondrial calcium levels (Schinder et al., 1996). Several groups have found that 
mitochondria are particularly susceptible to calcium-induced membrane depolarization in the presence of 
mutant Huntingtin (Fernandes et al., 2007).  
In summary, this HD-related mitochondrial vulnerability could stem from increased cytosolic calcium 
levels due to altered glutamate release and clearance, from increased calcium release from the endoplasmic 
reticulum, from slower recovery kinetics of mitochondrial calcium buffering (Fernandes et al., 2007), or 
increased mitochondrial sensitivity. In any case, depolarization of the membrane results in opening of the 
mitochondrial membrane permeability transition pore (MPTP), which releases cytochrome c and initiates 
apoptotic caspase signaling (Brustovetsky et al., 2002). Striatal neurons have proven to be particularly 
susceptible to this process of cell death, which may explain the selective degeneration in HD (Brustovetsky et 
al., 2003). Blockade of the MPTP formation by either cyclosporine A or bongkrekic acid were able to block 
NMDA-induced and HD-related striatal apoptosis highlighting the importance of this process for HD pathology 
(Fernandes et al., 2007; Zeron et al., 2002).  
Mitochondria may be especially dependent on proper manganese handling because manganese 
superoxide dismutase (MnSOD) is critical for detoxifying reactive oxygen species in the mitochondria, and 
manganese is a necessary cofactor for this activity. Manganese supplementation is known to increase MnSOD 
activity in lymphocytes, while iron supplementation decreases MnSOD activity presumably due to the inverse 
relationship between iron and manganese accumulation (Davis & Greger, 1992). Neuronal concentration of 
manganese is very low (< 10 µM); however, the demand for high mitochondrial activity in neurons may be the 
reason for increased MnSOD activity compared to that found in glia (M. Aschner & Aschner, 1991). 
Manganese deficiency results in decreased MnSOD activity and increased mitochondrial lipid peroxidation in 
rats (Zidenberg-Cherr et al., 1983), and HD patients have demonstrated increased lipid peroxidation in their 
CSF (Boll et al., 2008). Manganese deficiency also causes reduced oxygen uptake and dysmorphic elongation 
of mitochondria, likely due to lack of ROS detoxification (Hurley et al., 1970). 
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Partial loss of MnSOD in heterozygous knockout mice results in increased sensitivity to 3-nitroproprionic acid 
(Andreassen, Ferrante, Dedeoglu, Albers, et al., 2001). 3-nitroproprionic acid (3NPA) causes oxidative stress 
in neurons by inhibiting succinate dehydrogenase, complex II of the electron transport chain (Huang et al., 
2006). This uncoupling of the electron transport chain results in increased production of superoxide, a potent 
reactive oxygen species that can result in mitochondrial dysfunction as well as oxidative damage of proteins 
and DNA. 3NPA is also known to cause a preferential lesion to the striatum and was commonly used to model 
HD in rodents and primates prior to the cloning of HTT (Beal et al., 1993). Furthermore, cells expressing 
mutant Huntingtin are more susceptible to this toxicant (Gines et al., 2003; Williams, Kwakye, et al., 2010). 
Together, these data argue for a mechanistic link between MnSOD and HD via mitochondrial biology. 
Clearance of the toxic byproducts of cellular respiration is clearly inefficient in neurons bearing the HD gene 
mutation, but other functions, such as cellular energetics, are also impacted by mutant HTT, the delicate 
balance of intracellular metal ions, and possibly by the interaction between the two.   
Since mitochondria are the primary site of ATP production in the cell, mitochondrial function is tightly 
linked to ATP levels. Many disease models of HD demonstrate reduced ATP levels hinting at underlying 
mitochondrial dysfunction (Gines et al., 2003; Mochel et al., 2012; Seong et al., 2005; Weydt et al., 2006). 
Furthermore, a striking inverse relationship between ATP/ADP levels and CAG repeat lengths, both pathogenic 
and non-pathogenic, was observed in human lymphoblastoid lines(Seong et al., 2005). Defects in extra-
mitochondrial energy metabolism have been observed in mouse striatal models of HD (J.-M. Lee et al., 2007). 
In addition to the potential mitochondrial dysfunction via decreased MnSOD discussed in the previous section, 
reductions in important metabolites necessary for the TCA cycle can also lead to reduced mitochondrial 
respiration and ATP production. One important enzyme that produces metabolites for the TCA cycle is 
pyruvate carboxylase. 
Pyruvate carboxylase (PC) is a manganese-dependent enzyme that converts pyruvate to oxaloacetate, 
which is a metabolite for the TCA cycle (Scrutton et al., 1966). Deficiencies in PC can lead to increased lactate 
in the blood and lactic acidosis, a serious medical condition (Mochel et al., 2005). The activity of pyruvate 
carboxylase was found to be highly variable in post mortem brains of HD patients;(Butterworth, 1986) however, 
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many studies have found alterations that indicate reduced activity of this enzyme in HD patients. Lactate has 
reduced clearance in HD patients (Josefsen et al., 2010). Increased lactate was also seen in the frontal lobe, 
occipital lobe, and striata of HD patients (Harms et al., 1997; Jenkins et al., 1993). In addition to increasing 
lactate levels, reduced PC activity decreases the availability of metabolite precursors to the TCA cycle, which is 
the major source of ATP production. Reduced ATP levels have been seen in many disease models of HD 
(Gines et al., 2003; Mochel et al., 2012; Seong et al., 2005; Weydt et al., 2006). 
Additionally, n-acetyl aspartate (NAA), for which oxaloacetate (OAA) is a precursor, is decreased in the 
same areas that see an increase in lactate in HD, and both of these potential biomarkers for HD correlate in a 
concentration dependent manner with duration of the illness (Harms et al., 1997; Jenkins et al., 1993). There is 
a high concentration of NAA in brain, and production of NAA from OAA is an alternate route for the removal of 
free cellular ammonia via the addition of an amine (Chiosa et al., 1965). In fact, NAA is the second most 
abundant molecule in the brain after glutamate (Birken & Oldendorf, 1989). The urea cycle alterations seen in 
HD may be interconnected with HD-related reduction in NAA. Additionally, the amino acid asparagine, for 
which NAA is a precursor, is found to be reduced in HD patient brains with high predictive ability (Gruber et al., 
2013). Interestingly, creatine treatment can reduce the levels of lactic acid in patients with lactic acidosis 
(Rodriguez et al., 2007). Creatine has been shown in multiple HD mouse models to ameliorate many of the 
pathological phenotypes, including motor deficits, weight loss, hyperglycemia, and brain atrophy (Andreassen, 
Dedeoglu, et al., 2001; Ferrante et al., 2000). Although there may be other derangements of the TCA cycle 
stemming from the Huntington’s disease gene mutation, some of alterations that lead to increased lactate may 
be explained by the reduced regional uptake of manganese which is necessary for crucial cofactors in this 
cycle. 
In theory manganese deficiency, should lead to a reduction in pyruvate carboxylase activity; however, 
manganese deficient pups have elevated PC activity by postnatal day 3. Despite this finding, plasma glucose 
levels are reduced on postnatal days 1 and 2, suggesting glucose metabolism is compromised by manganese 
deficiency (Baly et al., 1985). PC expression may increase to compensate for diminished activity from a lack of 
available manganese, with this increase in PC production becoming evident once manganese is replaced in 
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the diet. Of note, gene expression profiling data from a striatal model of HD implicated several genes in 
glucose metabolism as being altered in HD, in particular expression of PCX (the gene which encodes PC) is 
elevated in an HD mutant line (J.-M. Lee et al., 2007). Thus, both HD models and manganese deficiency 
models in rodents result in increased PC expression or activity.  
 
IGF/PI3K/AKT signaling in HD and Manganese exposure 
Metabolic disturbances in HD may also be due to altered cell signaling via the insulin and IGF-1 pathways that 
regulate important rate limiting steps in energy production including glucose transport, glycogen synthesis, and 
production of precursors for the TCA cycle.  As described in section X.1, HD is a neurodegenerative disorder, 
with select regions showing severe neuronal death, indicating a cell-type specific response to the pathogenic 
mutation of the Huntingtin protein. Growth factors such as IGF-1 and BDNF have been shown be essential for 
the survival of striatal neurons, and lack of these growth factor signals may contribute to HD (Zuccato et al., 
2010). IGF signaling, and insulin to a lesser extent, lead to activation of the PI3K/AKT pathway, which is an 
important signaling cascade that promotes proliferation and cell survival. Insulin like growth factor 1 (IGF-1) 
can stimulate this pathway via the IGF-1 receptor (IGF-1R) and can also activate the insulin receptor as well.  
Several studies have found reduced activation of the AKT pathway as measured by the ratio of 
phospho-AKT(S473) over total AKT in HD cells from patients and mice (Colin et al., 2005; Maglione et al., 
2010; Williams, Kwakye, et al., 2010). The increased risk for developing diabetes and insulin resistance in 
Huntington’s disease may result from the altered ability of IGF-1 and insulin to activate AKT and its 
downstream targets (Farrer, 1985; Podolsky et al., 1972). Blood glucose levels have also been shown to be 
increased in mice expressing mutant Huntingtin, and HD patients have decreased cerebral glucose 
consumption (Hurlbert et al., 1999; Mazziotta et al., 1987).  Increased activation of the AKT pathway by IGF-1 
supplementation has been shown to protect striatal neurons from mutant Huntingtin induced toxicity indicating 
that this phenomenon may be important in HD neurodegeneration (Humbert et al., 2002b). An alternative route 
to ameliorate HD-related AKT dysfunction has been administration of ganglioside GM1, which is reduced in HD 
mice and patient fibroblasts (Maglione et al., 2010).  
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Several groups have reported alterations in AKT signaling with manganese deficiency and exposure 
although not in the context of Huntington’s disease. Manganese deficiency has been shown to decrease 
expression of both insulin and IGF-1 (Clegg et al., 1998). Alternatively, exposure to manganese has been 
shown to increase IGF-1 expression,(Hiney et al., 2011) increase AKT phosphorylation at serine473 in the 
striatum,(Cordova et al., 2012) and activate both AKT and iNOS activity in microglia (J.-H. Bae et al., 2006). 
These increases in AKT activity could be due to stimulation of IGF-1 and insulin production or via a more direct 
route resulting from an observed insulin-like mimetic activity of manganese (Baquer et al., 2003; Subasinghe et 
al., 1985).    
In any case, changes in manganese levels, perhaps via effects on insulin and IGF-1, result in altered 
glucose regulation and metabolism. Manganese deficiency has been shown to decrease glucose metabolism, 
insulin secretion, and insulin-induced glucose uptake while manganese exposure can cause hypoglycemia 
(Baly et al., 1984; Hassanein et al., 1966). In fact, one reported case of  “sweet urine disease” was effectively 
treated with a traditional folk remedy of alfalfa tea. The “sweet urine” was found to have both elevated glucose 
and manganese urinary output. The alfalfa tea was high in manganese and found to reduce the urinary glucose 
levels (Keen et al., 2000). Therefore, supplementation of manganese may be efficacious as a treatment in 
diabetes or to regulate blood glucose levels in HD patients where insulin-resistance and diabetes are common 
(Farrer, 1985; Hurlbert et al., 1999). AKT signaling, insulin secretion, and blood glucose regulation are all 
affected by both manganese and mutant Huntingtin, but other modifiers of the AKT pathway can also be 
altered through this gene-environment interaction. 
Protein phosphatase 1 (PP1) is an important phosphatase in many cellular signaling pathways, 
including the AKT pathway. In fact, PP1 has been shown to directly dephosphorylate AKT at serine 473 and 
p53 at ser15 (to be discussed further in section 3.5) (D. W. Li et al., 2006; L. Xiao et al., 2010). Interestingly, 
both AKT and p53 phosphorylation have been shown to increase with manganese exposure; however, this 
would presumably increase the ability of PP1 to dephosphorylate at these sites as well (J.-H. Bae et al., 2006; 
Williams, Kwakye, et al., 2010).  
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One of the many functions of PP1 is to regulate the function of glycogen synthase by dephosphorylation 
and, thereby, increase its activity. The increased glucose levels noted in Huntington’s disease model mice 
could indicate a deficiency in glycogen synthase activity. Glycogen synthase is also regulated by GSK3B, 
which phosphorylates and inhibits activity. Intriguingly, GSK3B inhibitors are protective in some HD models, 
possibly because of deficient ability of PP1 to dephosphorylate glycogen synthase (Carmichael et al., 2002). 
Further analysis is needed to elucidate the role of this manganese-dependent enzyme, PP1, in HD. 
 
P53 pathway in HD and manganese 
P53 is one of the most studied and interconnected cellular signaling molecules known. P53 is important for 
regulating nearly all cellular stress signals including: DNA damage, oxidative stress, and various other 
stressors by integrating cellular stress response pathways to elicit an appropriate pro-survival or apoptotic 
transcriptional response (Carvajal & Manfredi, 2013).  P53 has been implicated as a player in mutant 
Huntingtin mediated neurodegenerative processes, and this pathway is activated under low manganese 
exposure conditions. Therefore, the p53 pathway may be another point of intersection between manganese 
homeostasis and Huntington’s disease pathology.  
HD patients have been shown to have brain accumulation of p53 that correlates with disease stage. 
Many cellular models of HD have also shown increased p53 activation by phosphorylation at serine15 (B.-I. 
Bae et al., 2005; J. L. Illuzzi et al., 2011). Mutant Huntingtin is thought to bind to p53 and alter its function 
(Steffan et al., 2000). Additionally, when HD model mice were crossed onto a p53 knock-out background, 
nearly all of the pathogenic and behavioral phenotypes in HD were ameliorated, suggesting that p53 may play 
an important role in the disease-associated neurodegeneration (B.-I. Bae et al., 2005). Additionally, the 
mitochondrial depolarization and fragmentation phenotypes seen in HD human and mouse cell models were 
also shown to be diminished by using a inhibitor of p53 transcriptional activity (B.-I. Bae et al., 2005; X. Guo et 
al., 2013).  In fact, single-nucleotide polymorphism (SNP) variants of the P53 gene have also been found to 
strongly modify age at onset in HD. In fact, 12.6% of variability after taking CAG repeat length into account 
could be explained by p53 polymorphisms, further underscoring the importance of p53 in HD pathology 
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(Chattopadhyay et al., 2005). Finally, human induced pluripotent stem cells from HD patients also demonstrate 
increased activation of p53 as well as one of its upstream kinases, ATM (Jung-Il et al., 2012). ATM has also 
been implicated in abnormal activation and phosphorylation of p53 (Grison et al., 2011).  
P53 has been shown to be a metal-binding protein that relies on a divalent metal ion, Zn2+, to maintain 
its proper conformation (Meplan et al., 2000). The ability of Mn2+ to interact directly with p53 has not been 
explored. Cellular exposure to several other divalent metal ions (Cd2+, Cu2+, Zn2+, Co2+, Cr2+) has been shown 
to cause the activation of p53 as monitored by phosphorylation at serine 15, but manganese had not been 
investigated in this context (Matsuoka & Igisu, 2001; Ostrakhovitch & Cherian, 2004; Stenger et al., 2011; S. 
Wang & Shi, 2001). However, primates exposed to manganese showed increases in p53 dependent 
transcripts,(Guilarte et al., 2008) . 
In the context of DNA damage, ATM is the canonical kinase for p53, and its activity is increased in 
some HD models as evidenced by autophosphorylation at serine 1981 (Jung-Il et al., 2012). ATM is an 
important kinase in the double-stranded DNA break (DSB) repair process (Banin et al., 1998; Canman et al., 
1998). In this process, breaks in genomic DNA are associated with a change in the inactive dimer form of ATM 
being converted into an active monomer that phosphorylates important downstream targets which regulate 
DNA repair (MRN, gamma-H2AX), cell cycle arrest (CHK2, p53), and apoptosis (p53). ATM has also been 
recently shown to be activated by oxidative stress through an alternative process of dimer conjugation via a 
cysteine disulfide bond formation (Z. Guo et al., 2010). Manganese has been shown to be necessary for the in 
vitro enzyme activity of ATM as demonstrated by phosphorylation of downstream targets such as p53 at ser15 
(Chan et al., 2000; Z. Guo et al., 2010). While these studies roughly describe ATM as a manganese-dependent 
enzyme, the exact nature of the relationship between Mn and ATM activity is poorly defined. Manganese may 
be necessary for proper ATM function in the context of other stressors, or the manganese itself may elicit ATM 
activation via oxidative stress resulting in the dimerization pathway shown in Guo et al 2010. This seems 
possible given that very high concentrations of manganese (5 mM) used for activation of ATM and subsequent 
phosphorylation of p53. The nature of the activation of ATM and p53 via manganese exposure needs to be 
more clearly defined.	  
	   25	  
Due to the broad role of p53 in regulating metabolism, DNA repair, stress response, and apoptosis via 
both transcriptional and non-transcriptional means, p53 dysregulation is also closely related to several of the 
HD phenotypes explored in previous sections. For example, p53 regulates the IGF-1/AKT pathway by 
regulating the transcription of several AKT regulatory genes (e.g. IGFBP3, PTEN) (Feng et al., 2007; Feng & 
Levine, 2010; Levine et al., 2006). AKT also regulates p53 signaling by binding and phosphorylating HDM2, a 
major regulatory protein of p53 (Gottlieb et al., 2002).  
There is also a role for p53 in the mitochondrial dysfunction seen in HD.  The HD propensity for 
mitochondrial depolarization and fragmentation have been shown in cell culture to be blocked by a p53 inhibitor 
(pifithrin-α) and by knockdown of p53 expression, and p53 has been found to be integral to opening of the 
mitochondrial membrane transition pore and the release of cytochrome c (B.-I. Bae et al., 2005; X. Guo et al., 
2013; Mihara et al., 2003; Vaseva et al., 2012). Interestingly, both the activity and transcription of MnSOD, 
which detoxifies mitochondrial ROS, are also negatively regulated by activated p53 (Drane et al., 2001; Pani et 
al., 2000). Therefore, increased mitochondrial susceptibility to glutamate/Ca2+ excitotoxic processes could be 
due to observed increases in p53 activity, leading to either increased propensity to open the MPTP or by 
diminishing MnSOD expression and activity and thereby increasing reactive oxygen species production and 
mitochondrial dysfunction.   
Activation of p53 has also been shown to reduce glutamate uptake in astrocytes as well as increase the 
level of mitochondrial glutaminase, which generates glutamate and ammonia (W. Hu et al., 2010; Panickar et 
al., 2009; S. Suzuki et al., 2010). Thus, activation of p53 in HD or via manganese exposure could lead to 
increased glutamate production and decreased glutamate clearance from the synapse and increased ammonia 
levels all of which have been seen in HD models (see section X.3.2.1) (Chiang et al., 2007; Lievens et al., 
2001). The far-reaching effects of p53 in regulating the cellular transcriptome as well as its intimate regulation 
of cell signaling, mitochondrial health, and apoptosis provide a potential unifying theory for the broad effects of 
manganese homeostasis alterations.  
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Summary  
Metal toxicity and deficiencies can have many detrimental effects on the brain particularly the basal ganglia, 
which is also selectively susceptible in many neurodegenerative diseases such as HD and Parkinsonism. Iron, 
copper, and, more recently, manganese levels have been shown to be altered in patients and mouse models of 
HD. Interestingly, manganese seems to be regionally decreased in organisms containing the mutant Huntingtin 
protein. The underlying manganese homeostatic dysfunction may cause reduced activity of enzymes that 
depend on manganese as a cofactor. Reduced manganese levels can lead to many maladaptive phenotypes 
found in HD models including: urea cycle dysfunction, altered synaptic glutamate regulation, decreased energy 
production, increased oxidative stress, and altered cell signaling that regulates energy homeostasis and 
cellular stress. This close relationship between manganese levels and Huntington’s disease indicates that 
deepening our understanding of the underlying defect could lead to therapeutics that rescue deficient 
manganese levels ameliorating dysfunctional HD processes.  
 
Modeling HD with Human Induced Pluripotent Stem Cells 
 
Previous HD models  
Animal models have provided many important insights into HD disease mechanisms; however, a 
complementary human-based model would overcome several obstacles in HD research (Chamberlain et al., 
2008). Model systems have including the original 3-nitroproprionic acid lesioned rodent model followed by 
transgenic mice, rats, fish, flies, and monkeys as well as immortalized murine striatal cell lines (Brouillet et al., 
1999; Sipione & Cattaneo, 2001; Trettel et al., 2000). The divergent evolutionary time between rodents and 
humans has allowed for large genetic differences, and these interspecies genetic differences could alter 
disease mechanisms and gene-environment interactions. The most common HD model has been an exon1 
transgenic mouse referred to as R6/2 (Mangiarini et al., 1996). Neurodegeneration occurs extremely early 
throughout the brain in this model with noticeable loss of brain volume at postnatal day 60 and neuronal loss at 
day 45 (Stack et al., 2005); however, the huge amount of Huntingtin protein missing in this model could result 
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in missing key aspects of human Huntington’s disease. Furthermore, murine HD models with similar size polyQ 
repeats can have completely different phenotypes indicating the importance of genetics other than the CAG 
repeat region (Zuccato et al., 2010). Interestingly, the endogenous murine huntingtin only has a polyQ 
expansion of 7 CAG repeats while the human gene averages around 20, and the functional significance behind 
this difference could also alter disease mechanisms and environmental disease modification based on species 
(Zuccato et al., 2010).  
Using human cells and tissues would circumvent these interspecies genetic differences. Post-mortem 
tissues have provided an important supply of human HD culture material; however, since HD patients lose the 
majority of their striatal volume during disease progression, these tissues are even more limited. Peripheral 
tissues such as dermal fibroblasts can be propagated in culture for a limited time period, but differences in 
expression pattern between CNS and dermal cells reduce their usefulness for modeling neurodegeneration.  
 
Induced Pluripotent Stem Cells 
Until recently, post-mortem and peripheral tissues were the only human models available for 
neurodegenerative studies, but with the advent of induced pluripotent stem cell (iPSC) technology, this 
paradigm is changing. In 2007, Shinya Yamanaka’s lab first demonstrated the direct reprogramming the 
epigenetic status of human somatic cells into iPSCs, cells equivalent to embryonic stem cells (Takahashi et al., 
2007; Takahashi & Yamanaka, 2006). In this landmark study, four transcription factors (OCT4, KLF4, SOX2, 
and c-MYC) were introduced using retroviral integration into cultured human dermal fibroblasts. Within 30 days, 
iPSC colonies appeared in culture (Takahashi et al., 2007). After establishing these colonies into stable cells 
lines, the endogenous pluripotency genes were found to be epigenetically active and the retroviral constructs 
were silenced. Further studies have validated that the expression pattern, telomerase activity, mitochondrial 
regulation, and pluripotency of hiPSCs is similar to that of human embryonic stem cells (hESCs) (Armstrong et 
al., 2010; Suhr et al., 2009; Takahashi et al., 2007). 
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Figure 3. Scientific approach: from bedside to bench and back again. A schematic overview is given of the steps 
involved in deriving patient-specific neurons and how observations from experimentation with these neurons can 
potentially benefit patients. Fibroblasts harvested from a skin biopsy are transduced to become patient-specific human 
induced pluripotent stem cells (iPSCs). The human iPSCs are then differentiated into neurons that can be assessed for 
their response to the neurotoxicants of interest. The knowledge obtained from these experiments may directly benefit the 
patients or allow the testing of novel hypotheses related to disease pathogenesis.  
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Like human embryonic stem cells (hESCs), iPSCs can be differentiated into any cell type in the body. 
Patient-specific iPSCs have also been generated (e.g. HD, ALS, PD, Down syndrome, spinal muscular 
atrophy) providing researchers with patient-specific cell lines for in vitro disease modeling (Figure 3) (Dimos et 
al., 2008; Ebert et al., 2009; G. Lee et al., 2009; Park et al., 2008). Recent studies have also provided 
increased reprogramming efficiencies by small molecule incubation and integration-free iPSC induction 
techniques using cell permeable proteins and non-integrating DNA vectors(Jia et al., 2010; Lin et al., 2009; 
Zhou et al., 2009). One study has also shown induction of iPSCs from culturing T cells found in a single 
milliliter of blood (Seki et al., 2010).  
These technical advancements will soon provide a simple, integration-free patient-specific generation 
method for HD iPSC lines that can be differentiated into relevant cell types. Indeed, the Yamanaka lab further 
improved their original technique by developing a episomal non-integrating plasmid method of expressing the 
reprogramming genes that has proved highly efficient(Okita et al., 2011). Huntington’s disease was one of the 
first diseased iPSC lines ever generated (Park et al., 2008) and since that time a plethora of papers generating 
and using HD iPSC disease models have been published (An et al., 2012; Camnasio et al., 2012; Consortium, 
2012; Jeon et al., 2012; Jung-Il et al., 2012; Juopperi et al., 2012; X. Zhang et al., 2010). 
 
In vitro Differentiation to Medium Spiny Neurons 
With the correct incubation of signaling molecules, HD iPSC lines can then be differentiated into striatal 
neurons. Neurodevelopment requires many spatial-temporal signaling events that are complicated by the 
multiple roles of signaling molecules. Unfortunately, the majority of neurodevelopmental research has been 
based on murine embryo brain development, and the timing and function of human homologs cannot be 
assumed from these data. Using human pluripotent stem cells in vitro allows for elucidation of both normal and 
disordered human neurodevelopment. Several laboratories have already used human recombinant signaling 
proteins and small molecules to exogenously direct differentiation of iPSC and ESC in vitro cell cultures to 
enriched populations of motor neurons, midbrain dopaminergic neurons, and forebrain GABAergic and 
glutamatergic neurons(Aubry et al., 2008; Chambers et al., 2009; Dimos et al., 2008; Ebert et al., 2009; 
	   30	  
Gaspard et al., 2008; Kim et al., 2010; X.-J. Li et al., 2009). Neurons differentiated from HD and control iPSC 
could be used for in vitro studies of disease mechanisms, gene-environment interactions, drug-screening, and 
regenerative medicine.  
The first stage of human stem cell differentiation is toward one of the three germ layers: 
neuroectoderm, mesoderm, and endoderm. Neuroectoderm has been found to be the default tissue fate of 
epiblast culture, and cultured hESCs have been shown to be in an epiblast stage(Buecker et al., 2010; Muñoz-
Sanjuán & Brivanlou, 2002). Signaling by the TGF-β super family, including bone morphogenic proteins 
(BMPs), inhibits the formation of neuroectoderm (Vallier et al., 2004). In vivo, proteins like noggin bind to BMPs 
to block their signaling allowing default neural tissue to form. Initial neural induction studies used either the 
formation of embryoid bodies or co-culture with stromal cells. Unfortunately, embryoid bodies induce small 
numbers of neural cells, and stromal cells take several weeks to cause efficient neural induction followed by 
laborious mechanical picking of neural rosettes (Dhara & Stice, 2008). These difficulties were overcome when 
Chambers et al. induced ~80% PAX6-expressing cells, a neuroectodermal markers, in less than a week in 
monolayer hESC culture (Chambers et al., 2009; X. Zhang et al., 2010). This was achieved using noggin and a 
TGFβ small molecule inhibitor (Chambers et al., 2009). Noggin can also be replaced with dorsomorphin, a 
small molecule that blocks the downstream Alk-SMAD pathway of BMP signaling (Chambers et al., 2009; Kim 
et al., 2010). Unfortunately, iPSC lines have been found to be highly variable in their neural induction 
efficiencies (B.-Y. Hu et al., 2010). However, this variability may be attenuated with the production of iPSC 
lines screened by more strict validation methods. In any case, a large percentage of neural progenitors can be 
produced from iPSC lines.  
Medium spiny neurons (MSNs), which are particularly vulnerable in HD, develop in the lateral 
ganglionic eminence of the ventral telencephalon. Gradients of signaling molecules give developing 
progenitors positional identity. LGE progenitors need to be patterned by signaling molecules that lead to an 
anterior, ventral, and finally lateral position during the neural patterning process. The anterior-posterior axis is 
set up by anterior expression of Wnt inhibitors, Cerberus (also a BMP inhibitor) and dikkopf-1 (DKK1), and 
BMP inhibitors inducing anterior fate (Figure 4A) (Rallu et al., 2002). Sonic hedgehog (SHH), is secreted from 
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the floorplate of the neural tube, setting up the dorso-ventral axis by inhibiting the dorsally expressed Gli3 
repression of fibroblast growth factor (FGF) signaling (Figure 4B) (Hébert & Fishell, 2008). FGF is the major 
ventralizing signal of the CNS. FGF receptor knockouts lose most of the ventral region of the telenchepalon 
(Hébert & Fishell, 2008). However, incubation of chick lateral ganglionic eminence (LGE) explants, which 
normally develops into striatum, with FGF8 causes expression of medial ganglionic eminence (MGE) markers 
(Lupo et al., 2006). Therefore, FGF8 I is most likely dispensable for LGE induction. Several laboratories have 
incubated hESCs with exogenous DKK-1 and SHH to produce cells expressing ventral telencephalic 
markers(Aubry et al., 2008; X.-J. Li et al., 2009). 
To specify LGE identity over MGE requires the signaling molecule retinoic acid (RA)(Lupo et al., 2006). 
RA expression in chick embryos causes expansion of the LGE at the expense of both MGE and dorsal regions 
(Marklund et al., 2004). Additional studies have found RA receptor antagonists block the formation of 
LGE(Lupo et al., 2006). Few studies have used RA for the specification of LGE-like progenitors despite its 
apparent necessity. The ventral telencephalon has been shown to endogenously produce RA, which could lead 
to LGE patterning in vitro (Guillemot, 2005; Waclaw et al., 2004). However, for a more robust directed 
differentiation protocol, RA may be necessary. 
After patterning, neural progenitors must be induced to terminally differentiate into mature neurons. 
BDNF is a key molecule in striatal differentiation. It induces the expression of DARPP-32, and BDNF loss 
decreases striatal projection neuron markers and MSN dendritic arborization complexity (Bédard et al., 2006; 
Jain et al., 2001; Rauskolb et al., 2010). Additionally, exogenous expression of BDNF and noggin in the adult 
striatal ventricular zone has been found to reactivate nascent progenitors to become new MSNs (Chmielnicki et 
al., 2004). The first report of DARPP-32 positive MSN generation from human ES cells used a combination of 
BDNF with valproic acid and dibutryl-cyclic-AMP, two compounds known to increase striatal neurogenesis 
(Aubry et al., 2008; Bédard et al., 2006; Laeng et al., 2004). This paper from the Perrier lab showed that MSN-
like differentiation is possible; however, the protocol was highly inefficient and took nearly two months to 
complete. The most refined protocol for MSN-like differentiation(Carri et al., 2013) combines the SHH and 
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Figure 4. In vivo patterning of the telencephalon via endogenous signaling molecules. A Several important 
signaling molecules in anterior-posterior axis formation. Wnt and BMP promote posterior formation, and Cerberus, noggin, 
and dikkopf-1 inhibit the function of these posteriorizing molcules leading to anterior formation. B Major telencephalic 
signaling molecules. The three major regions are labeled on the left cortex (CTX), lateral ganglionic eminence (LGE), and 
medial ganglionic eminence (MGE). To the right are specific markers of these regions. Sonic hedgehog (SHH), fibroblast 
growth factors (FGF), retinoic acid (RA), Wnt, Foxg1, and Gli3 have both active and repressive roles in setting up the 
dorso-ventral and medio-lateral axes. 
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DKK1 (Aubry et al., 2008; X.-J. Li et al., 2009) after dual-SMAD inhibition (Chambers et al., 2009) followed by 
neurobasal medium with BDNF, N2, and B27 supplements. These cells were highly characterized as valid 
MSNs by immunostaining, microarrays, and electrophysiological recordings; however, the efficiency of 
DARPP-32 expressing cells was still 10%. 
 
Modeling Huntington’s disease with patient-specific iPSC derived neurons 
Although medium spiny neurons (MSNs) are the first cells affected in typical disease progression, current 
differentiation protocols to MSNs from iPSCs are highly inefficient and time-consuming (Aubry et al., 2008). 
While these protocols are being developed, many labs have begun using neural stem cells or neuroprogenitors 
to model Huntington’s disease allowing for more homogeneous cell populations for assay disease phenotypes 
(Camnasio et al., 2012; Consortium, 2012; N. Zhang et al., 2010). In fact, some publications have indicated a 
potential development role in Huntington’s disease (Molero et al., 2009); therefore, assaying disease 
phenotypes throughout in vitro development may provide new insights into the disease. Although there is no 
indication that early neural progenitors are affected in HD, new studies indicate that the specificity to MSNs is 
due to a quantitative regional difference of the neurodegenerative process rather than a region-specific 
qualitative difference (Fossale et al., 2011). In fact, many brain regions in addition to the striatum degenerate in 
late stage HD presumably for this reason (Zuccato et al., 2010). Furthermore, in juvenile HD nearly all regions 
of the brain degenerate. Therefore, since neural progenitors have a similar expression pattern to mature cells 
and mutant Huntington is expressed in all cells, we expect at least some of the neurodegenerative disease 
process to be active in neuroprogenitors. 
 Given the great breadth of Huntington’s disease related phenotypes in patients and both animal and 
cell models(Zuccato et al., 2010), initial experiments investigating genotype-phenotype relationships in HD 
iPSC models often rely upon the investigators prior experience. For this reason, nearly all of the HD iPSC 
papers published to date focus on different outcome measures. Thus far, HD related phenotypes shown in 
human iPS cell models have included increased caspase activity after growth factor withdrawal, increased 
lysosomal activity, reduced ATP levels, and accumulation of vacuoles(Camnasio et al., 2012; Consortium, 
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2012; Juopperi et al., 2012; N. Zhang et al., 2010). Many of these observations further validate disease 
differences shown in previous models systems(Castiglioni et al., 2012; Gines et al., 2003; Martinez-Vicente et 
al., 2010; Mochel et al., 2012; Nagata et al., 2004; Seong et al., 2005; Weydt et al., 2006). Recent advances in 
genome editing, such as the advent of CRISPR technology, provide the ability to create isogenic control lines 
to reduce the possibility of none genotype related phenotypes from other genetic differences between control 
and HD lines(Hou et al., 2013).  One HD iPS cell study replaced a pathogenic 72 CAG repeat length in the 
mutant allele with a non-pathogenic length of 21 CAG repeats(An et al., 2012). This contraction of the repeat 
region eliminated elevations in apoptosis, caspase cleavage, reduced BDNF, TGF-β1, and N-Cadherin 
expression. With the rapid progression in efficiency and accessibility of CRISPR technology, these types of 
controls should soon become standard to iPS cell model research. 
 
Conclusion 
Induced pluripotent stem cells will provide an important model for the study of Huntington’s disease. These 
cells can be generated from patients with well-documented genotypes and symptoms in much less time than 
generating a transgenic mouse. They can be propagated indefinitely and differentiated into medium spiny 
neurons. In vitro differentiation allows for better understanding of human neurodevelopment and how disease 
and toxicants affect developmental time points. Maintenance of the human genetic background allows for an 
adequate model to study gene-environment interactions, and these studies could lead to treatments that delay 
disease onset and progression for HD patients.  
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CHAPTER II 
 
A MANGANESE-HANDLING DEFICIT IN HUNTINGTON’S DISEASE SELECTIVELY  
IMPAIRS ATM-p53 SIGNALING  
 
The essential micronutrient manganese is enriched in brain, especially the basal ganglia. We sought to identify 
neuronal signaling pathways responsive to neurologically relevant manganese levels, as previous data 
suggested manganese alterations occur in Huntington’s Disease (HD). We found that p53 phosphorylation is 
highly responsive to manganese levels in human and mouse striatal-like neuroprogenitors. The Ataxia 
Telangiectasia Mutated (ATM) kinase is responsible for this manganese-dependent phosphorylation of p53. 
Activation of ATM-p53 by manganese was severely blunted by pathogenic alleles of Huntingtin. HD 
neuroprogenitors exhibited a highly manganese selective deficit in ATM kinase activation, since DNA damage 
and oxidative injury, canonical activators of ATM, did not show similar deficits. Manganese was previously 
shown to activate ATM kinase in cell-free assays. We found that human HD neuroprogenitors have reduced 
intracellular manganese with neurologically relevant manganese exposures. Pharmacological manipulation to 
equalize manganese between HD and control neuroprogenitors rescued the ATM-p53 signaling deficit.  
 
Introduction 
Huntington’s disease (HD) is a devastating neurological disorder characterized by motor, psychological, and 
cognitive impairments and premature death (Zuccato et al., 2010). Symptoms stem primarily from central 
nervous system (CNS) neurodegeneration - most notably death of medium spiny neurons (MSNs) in the 
caudate and putamen. HD is caused by an expansion of a CAG triplet-repeat region in exon 1 of the Huntingtin 
gene. Although HD is a monogenic, autosomal-dominant disease, environmental factors play a major role in 
modifying age of disease onset. CAG repeat length contributes to just over half of the variability in age of 
onset, and the majority of the remaining age of onset variability was attributed to unknown environmental 
factors in a landmark genetic study of a large Venezuelan kindred (Wexler, 2004). For example, among 
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patients with repeat lengths of ~40, ages of onset can span four decades or more (Wexler, 2004). Even 
monozygotic twins with HD have shown differences in both age of onset (differences up to 7 years) and 
symptomatic manifestation, despite identical repeat lengths (Anca et al., 2004; Friedman et al., 2005; Georgiou 
et al., 1999). These data strongly support a role for environmental modifiers in HD pathobiology, even though 
few specific environmental modifiers have been discovered. Aside from environmental enrichment in HD 
mouse models, metals (copper, iron, cadmium, and manganese) are important environmental modifiers of HD 
(Fox et al., 2007; Glass et al., 2004; Wild & Tabrizi, 2007; Williams, Li, et al., 2010; G. Xiao et al., 2013). We 
have previously shown differential toxicological sensitivity to manganese (Mn2+) and cadmium (Cd2+), but not 
other metal ions tested (Fe3+, Cu2+, Pb2+, Co2+, Zn2+, Ni2+) in an immortalized mouse striatal neuroprogenitor 
model of HD (STHdhQ7/Q7 and STHdhQ111/Q111) (Trettel et al., 2000; Williams, Li, et al., 2010). Expression of 
mutant Huntingtin conferred a survival advantage under cytotoxic manganese exposure conditions due to a 
substantial decrease in net manganese uptake, whereas mutant Huntingtin increased sensitive to cadmium 
cytotoxicity (Williams, Li, et al., 2010).  
Manganese, an essential element, is required for several enzymatic processes (J. L. Aschner & 
Aschner, 2005), and several of the processes are altered in HD (e.g. oxidative stress, glutamate cycling, and 
the urea cycle) (Bowman, Kwakye, Herrero Hernández, et al., 2011). On the other hand, excess manganese 
causes cytotoxicity via increased oxidative stress in part from direct inhibition of mitochondrial respiration (S. 
Zhang et al., 2004). Thus, appropriate homeostatic regulation of manganese levels is needed to ensure 
biological function but avoid toxicity (Santamaria, 2008) . The globus pallidus, caudate nucleus, and other 
areas of the basal ganglia contain the highest level of manganese in the brain and are the areas most 
susceptible to HD degeneration (Larsen et al., 1979; Prohaska, 1987). Pre-symptomatic HD mice  (Tg-
YAC128Q) have elevated sensitivity to manganese exposure, with increased dendritic spine loss in MSNs 
(Madison et al., 2012). HD patients also have reduced manganese levels in cortical regions, and manganese 
exposed HD mouse models have reduced manganese accumulation in the striatum, the most vulnerable 
region in HD(H Diana Rosas et al., 2012; Williams, Li, et al., 2010). Collectively, these data suggested a 
potential alteration in brain manganese-handling in HD. In this study, we assessed whether biological 
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responses to manganese are altered by pathogenic CAG repeat expansions in Huntingtin using human 
induced pluripotent stem cell (iPSC)-derived early striatal-like (ventralized) forebrain lineage neuroprogenitors 
and mouse STHdh striatal neuroprogenitors (Carri et al., 2013; Chambers et al., 2009; Ma et al., 2012; Okita et 
al., 2011).  
We postulated that manganese exposure and mutant Huntingtin may impinge upon common 
intracellular signaling pathways. Manganese exposure increases AKT and ERK phosphorylation in the rat 
striatum, and mouse striatal and microglial cultures (J.-H. Bae et al., 2006; Cordova et al., 2012; Williams, Li, et 
al., 2010). Manganese exposure in non-human primates elicited alterations in p53-dependent transcripts and 
increased p53 immunoreactivity in the frontal cortex (Guilarte et al., 2008). Additionally, in PC12 cells, 
manganese can increase p21 mRNA expression, an established transcriptional target of p53 (Zhao et al., 
2012). Expression of mutant Huntingtin has also been shown to alter AKT (Colin et al., 2005; Cordova et al., 
2012; Humbert et al., 2002a; Williams, Li, et al., 2010), p53 (B.-I. Bae et al., 2005; Steffan et al., 2000), ERK 
(Apostol et al., 2006; Fan et al., 2012), mTOR (Ravikumar et al., 2004), AMPK (Ju et al., 2011), and GSK3β 
(Carmichael et al., 2002) signaling. However, most of the manganese studies were performed at acutely 
cytotoxic levels of manganese. To test the hypothesis that expression of mutant Huntingtin would alter 
intracellular signaling in response to neurologically-relevant manganese levels, we assessed the response of 
several signaling pathways to sub-cytotoxic levels of manganese in human and mouse striatal-like 
neuroprogenitor models of HD.  
 
Results 
 
Generation and validation of human HD patient and control iPSC lines  
We generated iPSC lines from dermal fibroblasts (Coriell Cell Repositories [GM21756 and GM09197]) of 2 
juvenile-onset HD patients with large Huntingtin CAG repeat lengths (70 and 180). We also derived iPSC lines 
from fibroblasts of 2 control subjects with no history of neurological conditions (CE and CF) (see Materials and 
methods). Integration-free iPSC lines were generated by electroporating fibroblasts with episomal plasmid 
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vectors (Okita et al., 2011). The iPSC lines were validated for expression of protein markers of pluripotency 
such as OCT4 and Nanog (Figure 5A). HD genetic status was confirmed by assessing the CAG repeat length 
in exon 1 of Huntingtin in both the iPSC lines and the originating fibroblast lines (Figure 5B). We identified one 
clonal line, HD180 clone 6 (referred to as HD180-6), that demonstrated an expansion of the CAG repeat from 
180 to >210 in the pathogenic allele. To our knowledge, this is the first reported expansion of the Huntingtin 
gene CAG repeat region in an iPSC line; however, iPSC lines from patients with Friedrich’s ataxia often 
demonstrate expansion of the GAA triplet repeat due to high expression of MSH2, which is known to mediate 
somatic triplet expansion in the Huntingtin gene (Ku et al., 2010; Manley et al., 1999). To validate the quality of 
our iPSC lines, we performed PCR for DNA isolated from each clonal iPSC line to ensure the absence of 
plasmid integration. The episomal vectors are typically lost over successive cell cycles; however, they can 
integrate into the genome at a low frequency (Okita et al., 2011). Primers were targeted to the WHP 
Posttranscriptional Regulatory Element (WPRE) region of the plasmid that would constitute a novel sequence 
in the human genome. Lines maintaining the WPRE region were excluded from our studies. A normal euploid 
karyotype was confirmed for all validated lines. Lastly, we performed an mRNA microarray and performed the 
PluriTest bioinformatics assay to test for conformity to pluripotency (Figure 5C). All iPSC lines used in this 
study were confirmed by this test with very little variance between lines and high similarity to a previously 
published teratoma-validated control line (Neely et al., 2012). 
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Figure 5. Differentiation of iPSCs into early striatal-like neuroprogenitors. (A) Immunofluorescent staining of HD 
iPSC line HD70-2 for markers of pluripotency. (B) PCR for the Huntingtin gene including the CAG repeat region. The lower 
bands are the non-pathogenic alleles, and the larger bands are pathogenic. All iPSC lines show similar sizes to the 
fibroblast lines from which the iPSCs were generated except HD180-6, which shows an expanded CAG repeat size. (C) 
The PluriTest analysis was used to validate the mRNA microarray profile from our iPSC lines, and all lines had a similar 
pluripotency profile, including a teratoma-validated iPSC line. (D) Control (CA-24) and HD (HD180-2) iPSCs were 
differentiated to early forebrain neuroprogenitors by the dual SMAD small molecule technique with and without 
purmorphamine (SHH agonist) and were immunostained for ISL1 (red), a marker of striatal progenitors, with nuclei labeled 
with Hoechst dye (blue). (E) Expression of markers of neurodevelopment was measured by qRT-PCR from the CF-3 
control cells differentiated with and without purmorphamine. ** for p < 0.01, *** p < 0.001 by t-test. N = 4. Mean ± SEM. 
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Differentiation to neuroprogenitors expressing early striatal markers  
We used the established “dual-SMAD inhibition” method of neuralization via SB431542 and DMH1 to generate 
telencephalic neural progenitors from our iPSC cultures (Chambers et al., 2009; Ma et al., 2012; Neely et al., 
2012). These early neuroprogenitors expressed the neuroectodermal marker, PAX6, and the telencephalic 
marker, FOXG1 (Figure 5E)(X. Zhang et al., 2010). Addition of sonic hedgehog (SHH) or a SHH agonist, 
purmorphamine, has been shown to ventralize these neuroprogenitors to express markers of the lateral 
ganglionic eminence (LGE) from which striatal MSNs develop (Ma et al., 2012). Addition of purmorphamine to 
the neuroprogenitor cultures from day 4 of differentiation onward resulted in a significant increase in expression 
of Islet1 (ISL1) protein and mRNA over time (Figure 5D, E). In the developing telencephalon, ISL1 is 
expressed specifically in the earliest post-mitotic cells of the striatum (H.-F. Wang & Liu, 2001). A recently 
published method for generating fully validated MSNs uses an analogous technique in the first stage (Carri et 
al., 2013). Our ISL1+ neuroprogenitors provided a nearly homogenous cell population (~90% ISL1+ cells by 
immunofluorescence microscopy) regardless of the genotype (HD or control) to begin assessing the effects of 
manganese. Furthermore, quantitative reverse-transcriptase PCR (qPCR) for lSL1 demonstrated statistically 
identical expression levels between control and HD neuroprogenitors (Figure 6). These human striatal-like 
neuroprogenitors are at a homologous developmental time point as the STHdhQ7/Q7 and STHdhQ111/Q111 cells, 
which were isolated from the mouse striatum on embryonic day 14 (E14), a developmental time point wherein 
ISL1 expression defines the developing striatum (López-Bendito et al., 2006; Trettel et al., 2000). Thus, 
allowing for more valid comparisons between these two model systems. 
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Figure 6. ISL1 mRNA expression is the same in control and HD human neuroprogenitors. On day 12 of 
differentiation, mRNA samples were obtained from control and HD cells. Quantitative RT-PCR was performed on 10 ng of 
cDNA, and the values were normalized to actin and ribosomal RNA expression. N = 4 for control (2 each for CE-6 and CF-
1) and HD (2 each for HD70-2 and HD180-4). Bars, mean + SEM. 
 
Manganese exposure evokes strong p53 response in human and mouse striatal neuroprogenitors 
To elucidate the effect of sub-toxic manganese exposure on intracellular signaling pathways in both the human 
and mouse cell models, we performed the PathScan ELISA-based signaling pathway array (PathScan, Cell 
Signaling Technology, Danvers, MA). The sub-toxic manganese exposure (24-hour) concentrations in the 
human and mouse neuroprogenitors were determined via the CellTiterBlue cell viability assay (Promega, 
Madison, WI) (Figure 7). In human ISL1+ neuroprogenitors, no difference in manganese cytotoxicity was 
observed between HD and control (Figure 7A). This finding is in contrast to the decreased sensitivity of mouse 
HD STHdhQ111/Q111 cells to manganese cytotoxicity relative to control shown here (Figure 7B) and previously 
published (Williams, Li, et al., 2010). We selected 200 µM manganese exposure for the human ISL1+ 
neuroprogenitors, and 50 µM manganese for the mouse striatal STHdh cells because these concentrations 
caused similar, but minimal (< 15%), loss of viability across the two model systems (Figure 7C). These 
concentrations are at, or just above, the threshold associated with brain toxicity in vivo (Bowman & Aschner, 
2014). Furthermore, these manganese levels are within the range we previously found to elicit a strong 
HD/manganese interaction in the mouse STHdh model (Williams, Kwakye, et al., 2010; Williams, Li, et al., 
2010).  
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Figure 7. Manganese-induced loss of viability in human neuroprogenitors is unaffected by mutant Huntingtin. 
The cell viability assay, CellTiterBlue, was performed on human (A) and mouse (B) neuroprogenitors. The signals were 
normalized by defining the vehicle treated cells as 100% viability. The data for 200 µM manganese exposure in humans 
and 50 µM in the mouse STHdh cells (Q7 and Q111), labeled here with arrowheads in A and B, were replotted for further 
comparison (C). N = 6 for control and 5 for HD in human neuroprogenitors, and N = 6 wells in mouse striatal cells. For 
genotype comparisons * for p < 0.05, ** p < 0.01, *** p < 0.001 by t-test. Bars, mean + SEM (A) and SD (B,C). 
 
The PathScan array was used to assess manganese-induction of 18 unique signaling events (phosphorylation 
or proteolytic cleavage) in control and HD neuroprogenitors (Figure 8). Phosphorylation of several signaling 
proteins displayed a manganese-dependent increase in control cells (Human: p53 and AKT; mouse: p53, 
GSK3β, and AKT). Phosphorylation of p53 at serine-15, p53(S15), and phosphorylation of AKT at threonine-
308 were significantly changed in both model systems, with phosphorylation of p53(S15) showing the most 
robust change in both human and mouse models (Figure 8A,B). Interestingly, manganese-induced 
phosphorylation of p53(S15) was severely diminished in HD neuroprogenitors in both human (223% in control 
vs. 113% in HD; p < 0.01) and mouse striatal-like neuroprogenitors (384% in control vs. 163% in HD; p < 0.05). 
As expected from our cytotoxicity assays, proteolytic activation of Caspase-3 and PARP-1, enzymes activated 
during apoptotic cell death, showed no change between vehicle and manganese exposures, indicating minimal 
apoptotic cell death in our PathScan array experiments (Figure 8C,D). We suspect the slight decrease in 
detected viability by the CellTiterBlue assay at these manganese exposure levels (Figure 7A) is due to 
decreased cell proliferation over the 24-hour exposure period, rather than cell death. 
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Figure 8. PathScan ELISA array shows manganese-induced phospho-p53(S15) at sub-cytotoxic manganese 
concentrations. (A) Human cells were exposed for 24 hours to 200 µM Mn2+. N = 2 for control (CE-6 and CF-1, once 
each) and HD (HD70-2 and HD180-6, once each). (B) Mouse STHdh neuroprogenitors (Q7 and Q111) cells were 
exposed for 24 hours to 50 µM Mn2+. (A,B) Phosphorylation and cleavage events were measured by the Fluorescent 
PathScan Intracellular Signaling Array sandwich ELISA. Background from no protein sample was subtracted, and signals 
were divided by the mean of the untreated samples by genotype. The array was imaged and quantified using an Odyssey 
IR imager. Antibodies whose signal was less than 4 times the background were not plotted. For both human and STHdh 
cells this included phosphorylation at Stat1-Tyr701, HSP27-Ser78, p38-Thr180/Tyr182, PARP-1 cleavage, and caspase-3 
cleavage. For human cells (A) phosphorylation at Stat3-Tyr70 was below detection, and phosphorylation of mTOR-
Ser2448, p70 S6 Kinase-Thr389, and SAPK/JNK-Thr183/Tyr185 were below detection for the mouse striatal cells (B). 
(C,D) The PathScan values for caspase-3 and PARP-1 cleavage are plotted relative to background fluorescence with N=2 
for human cells (C) and N=3 for mouse (D). # for p < 0.05 compared to vehicle-treated by t-test. For genotype 
comparisons * for p < 0.05, ** p < 0.01 by t-test. Bars, mean + SEM for A,B and + SD for C,D.  
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Phosphorylation of p53 by manganese is dose-dependent and deficient in HD mutant cells 
Western blot analysis was used to further assess the manganese and HD/manganese interaction effects on 
p53(S15) phosphorylation. Manganese-induced phosphorylation of p53(S15) was concentration-dependent 
(Figure 9A,B). The control lines (CE-6 and CF-1) had substantially greater phosphorylation with manganese 
treatment (at 100 and 250 µM) than the HD mutant lines (HD70-2 and HD180-6) (e.g. 418% in control vs. 
169% in HD at the 250 µM manganese exposure, p < 0.01) (Figure 9A,B). Human and mouse HD 
neuroprogenitors showed a small, but significant, manganese-induced p53(S15) phosphorylation, that was 
significantly blunted compared to control cells. Levels of total p53 were also significantly increased by 
manganese exposure in the control cells (p < 0.01), but not enough to account for the differences in 
phosphorylation (2.1 fold increase in total p53 vs. 4.2 fold increase in phosphorylated p53[S15]) (Figure 9C). 
The mouse striatal neuroprogenitor model showed a similar dose-dependent phosphorylation of p53(S15) with 
a strong deficit in HD cells (Figure 9F,G). Control mouse neuroprogenitors also showed a manganese-
dependent increase in the p53 transcriptional target p21 (CDKN1A) mRNA expression (6.87 fold increase 
above vehicle, p < 0.001), while the HD mutant cells did not (with only a non-significant 1.82 fold increase 
above vehicle)(Figure 10). Elevated expression of this canonical p53 transcriptional target is highly consistent 
with manganese exposure increasing p53 transcriptional activity. To determine if the HD/manganese 
interaction effect occurred with other manganese-responsive phosphorylation events, the same blots were 
probed for phosphorylation of AKT at serine-473 (S473), a known manganese-responsive signaling event 
(Cordova et al., 2012; Williams, Li, et al., 2010). Manganese exposure was associated with a dose-dependent 
increase in phosphorylation of AKT(S473), as expected, but unlike p53(S15), the HD cells had a similar degree 
of phosphorylation as the controls (Figure 9D).  
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Figure 9. HD striatal progenitors show reduced manganese-dependent p53(S15) phosphorylation. (A) Human cells 
exposed to manganese were probed by western blot for phospho-p53(S15) and total p53. (B,C) Western blot data was 
quantified and demonstrates significant differences in p53 phosphorylation between genotypes. N = 4 for control (CE-6 
and CF-1, twice each) and HD (HD70-2 and HD180-4, twice each). (D,E) Quantification of western blot data for phospho-
AKT(S473) and total AKT. N = 4 for control (CE-6 and CF-1, twice each) and HD (HD70-2 and HD180-4, twice each). 
(F,G) Mouse control and HD STHdh cells were exposed to manganese for 24 hours followed by western blot analysis for 
phos-p53(S15) and total p53. # for p < 0.05 compared to vehicle-treated by t-test.  * p < 0.05, ** p < 0.01, *** p < 0.001 by 
t-test. N=3. Bars, mean + SEM.  
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Figure 10. Manganese induces p21 (CDKN1A) mRNA expression but not in HD cells. Mouse STHdh 
neuroprogenitors (Q7 and Q111) were exposed to 50 µM manganese or vehicle. Quantitative RT-PCR was performed on 
10 ng of cDNA, and the values were normalized to actin expression. N = 3 for each. ** < 0.01 by t-test. Bars, mean + 
SEM.  
 
To further validate our western blot findings, we performed immunostaining for phosS15-p53 and total p53 in the 
mouse striatal cells exposed to vehicle or 50 µM manganese (Figure 11). The manganese-dependent increase 
in nuclear localized phosphorylated (S15) p53  can be seen in Q7 but not Q111 cells.  
 
Figure 11. Immunostaining confirms manganese dependent increase in p53 phosphorylation with deficit in HD 
cells.  Cells were immunostained for phosphoS15-p53 and total p53 after 24 hours of treatment in either vehicle or 50 µM 
manganese supplemented medium.  
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ATM activity is required for manganese-dependent p53 activation 
ATM, AMPK, ERK1/2, and p38 are known to phosphorylate p53(S15) (Banin et al., 1998; Canman et al., 1998; 
Jones et al., 2005; She et al., 2000). We did not see a manganese-dependent increase in phosphorylation of 
AMPK-α (threonine-172), ERK1/2 (threonine-202/tyrosine-204), or p38 (threonine-180/tyrosine-182) by the 
PathScan array, but ATM kinase was not on the array. High concentrations of manganese (5 mM) have been 
reported to activate ATM (ataxia telangiectasia mutated) to induce phosphorylation of p53(S15) in cell-free 
kinase assays (Banin et al., 1998; Canman et al., 1998; Chan et al., 2000; Z. Guo et al., 2010).  
 First, we measured ATM autophosphorylation at serine 1981, an indicator of activated ATM kinase, in 
the Hdh mouse striatal cells (Figure 12). We found a similar pattern of phosphorylation as phosphorylation of 
p53 at serine 15 (Figure 9F) with a deficit in manganese-dependent phosphorylation in the mutant huntingtin 
expressing Q111 cells. Next, we tested the hypothesis that blocking ATM kinase activity during manganese 
exposure would inhibit p53(S15) phosphorylation. We observed by both an In-Cell Western assay (Figure 
13A) and ELISA Array (Figure 13G) that the selective ATM inhibitor, KU-55933, completely blocked the 
manganese-dependent phosphorylation of p53 in the human neuroprogenitors (Hickson et al., 2004).  
 
 
Figure 12. HD striatal cells show reduced manganese-dependent ATM autophosphorylation (S1981). Mouse 
STHdh neuroprogenitors (Q7 and Q111) were exposed to 25, 50, or 125 µM manganese or vehicle. Western blot analysis 
was performed probing for phos(S1981)-ATM. N = 3 for each. # for p < 0.05 compared to vehicle-treated by t-test.  * p < 
0.05, ** p < 0.01, by t-test. N=3. Bars, mean + SEM. 
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Figure 13. Manganese induces phosphorylation of 3 ATM targets, which is blocked by ATM kinase inhibitor, KU-
55933. “In-Cell Western” was performed on human neuroprogenitors for phosS15-p53 (A,B), phosT68-CHK2 (C,D), and 
phosS139-H2AX (ie γ-H2AX) (E,F) and  with exposure to Mn at 200 µM (A,C,E) or DNA damaging agent, neocarzinostatin 
at 100 ng/mL (NCS) (B,D,F). The cells were also exposed to ATM inhibitor, KU-55933 at 1 µM. N = 4 for control (CE-6, 
CF-3; 2 experiments each) and N = 4 for HD (HD70-2, HD180-4; 2 experiments each). (G) PathScan data comparing 200 
µM Mn2+ treated control cells (CE-6 and CF-1) with and without the selective ATM inhibitor, KU-55933 (1 µM). N =2. # for 
p < 0.05 compared to vehicle-treated by t-test.  * < 0.05, ** < 0.01 *** < 0.001 for t-test between genotypes.  
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The effect of the inhibitor was quite specific to p53 phosphorylation, as no significant effects were observed for 
other signaling proteins on the PathScan array (Figure 13G). DNA damage is a canonical activator of the 
ATM-p53 signaling pathway. To test whether the ATM-p53 pathway is broadly deficient in its ability to respond 
to any pathway-relevant stressor in HD neuroprogenitors, we exposed the cells to neocarzinostatin, a double-
stranded DNA break (DSB)-inducing agent known to activate p53 via ATM (Banin et al., 1998). In contrast to 
the HD deficit in manganese-induced p53 activation, the human HD neuroprogenitors were hyper-sensitive to 
p53(S15) activation by neocarzinostatin (Figure 13B), and this phosphorylation was completely blocked by the 
ATM inhibitor, KU-55933, confirming activation occurred via ATM kinase. 
To further validate that ATM kinase is activated by manganese, we measured phosphorylation of two 
other established targets of ATM kinase, CHK2 at threonine-68 (T68) and H2AX at serine-139 (S139, i.e. γ-
H2AX). Using the In-Cell Western assay, control neuroprogenitors had a significant increase in 
phosphorylation of CHK2(T68) with manganese exposure, but CHK2(T68) was non-responsive in HD 
neuroprogenitors (Figure 13C). H2AX(S139) showed the same trend but with greater variance at the same 
sample size (N=4) (Figure 13E). In both cases, the ATM inhibitor KU-55933 completely blocked manganese-
dependent phosphorylation. Both ATM kinase targets were activated by the DNA-damaging agent 
neocarzinostatin with elevated phosphorylation in HD cells compared to control (Figure 13D,F). These data 
demonstrate a deficit in ATM activation by neurologically relevant levels of manganese in HD neuroprogenitors; 
yet, a fully responsive (or even hyper-responsive in the human HD neuroprogenitors) ATM kinase activity from 
a canonical activator of this pathway, DSB DNA damage. 
 
The HD-dependent deficit in ATM activation is specific to manganese 
Oxidative stress was recently discovered to activate ATM via a mechanism independent from the DNA 
damage-dependent activation of ATM (Z. Guo et al., 2010). To test whether ATM kinase is responding to 
manganese via an oxidative stress-dependent mechanism, we exposed the STHdhQ7/Q7 and STHdhQ111/Q111 
striatal neuroprogenitors to 250 µM hydrogen peroxide for 1 hour and measured the phosphorylation of 
p53(S15) and H2AX(S139) by In-Cell Western assay. We observed an equivalent phosphorylation of ATM 
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targets by hydrogen peroxide in HD and control cells (Figure 14A,B), with levels of phosphorylation of 
p53(S15) and H2AX(S139) equivalent to that observed after neocarzinostatin exposure (100 ng/mL for 1 hour). 
These observations suggest that hydrogen peroxide and manganese activate ATM via different mechanisms.  
 
 
Figure 14. Mutant Huntingtin only inhibits manganese-dependent ATM target phosphorylation. (A,B) Mouse 
STHdh striatal neuroprogenitors (Q7 and Q111) were exposed to manganese (50 µM) for 24 hours, neocarzinostatin 
(NCS, 100ng/mL) for 1 hour, or hydrogen peroxide (H2O2, 250 µM) for 1 h. (C,D) Mouse striatal cells were exposed for 24 
hours to several divalent metal cations all at 50 µM, except 100 µM Cu2+ and 20 µM Cd2+. The means are normalized by 
the vehicle mean for that line to allow for easier genotype comparisons. (E,F) Mouse striatal cells were also exposed to 
manganese (50 µM) for increasing amounts of time. Significant differences are designated as: a is significantly different 
from b and b is significantly different from c. If no letters are listed, then none of the means are significantly different from 
on another. # indicates significantly different from vehicle treated (p < 0.05 by Tukey’s post-hoc). N = 3 for means from 3-5 
wells for independent replicate experiments (A,C,E). N = 4 for means from 3-5 wells for independent replicate experiments 
(B,D,F). * < 0.05, ** < 0.01 *** < 0.001 for t-test between genotypes. Bars, mean ± SEM. 
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In the mouse STHdh neuroprogenitors, the ATM inhibitor, KU-55933, did not effectively block manganese or 
neocarzinostatin induced p53 phosphorylation at 1 µM (the concentration used in the human neuroprogenitors) 
but was partially effective at 20 µM (Figure 15). At this concentration, the inhibitor likely has off-target effects 
(Hickson et al., 2004). Nonetheless, we confirmed that KU-55933 decreased manganese-dependent p53 
phosphorylation in the mouse striatal neuroprogenitors.   
 
	  
Figure 15. KU-55933 inhibits the ATM dependent target phosphorylation in mouse striatal cells. Mouse STHdh 
neuroprogenitors (Q7) were exposed to either manganese (50 µM) for 24 hours, neocarzinostatin (NCS) or hydrogen 
peroxide (H2O2) for 1 hour with or without 1 µM (A) or 20 µM (B) KU-55933. The mouse phos-p53(S15) antibody was 
used in A  and rabbit phos-p53(S15) in B. N=5 wells from one independent experiment. ***  means p < 0.001 by t-test. 
Bars, mean + SD.    
 
We tested the hypothesis that the HD/manganese interaction effect on the ATM-p53 pathway is related to a 
generic metal response pathway, by exposing the mouse striatal neuroprogenitors to other divalent metal ions 
(Cd2+, Co2+, Cu2+, Ni2+, and Zn2+) and assessing ATM phosphorylation targets (Figure 14C,D). The same sub-
cytotoxic manganese concentration (50 µM) was used for all the metals except copper (100 µM) and cadmium 
(20 µM), as higher concentrations of cadmium resulted in cytotoxicity (Williams, Li, et al., 2010). We found that 
other metals either significantly increased (Cd2+, Co2+), decreased (Ni2+, Zn2+), or did not affect (Cu2+) p53(S15) 
and H2AX(S139) phosphorylation; however, except for cadmium (Cd2+), the changes in p53 phosphorylation 
were quite small compared to that observed with manganese. None of these other metals, however, showed 
an HD-dependent deficit in p53(S15) phosphorylation.  
We tested the hypothesis that the HD-dependent differences in ATM activity at 24 hours may be due to 
altered response kinetics to manganese (e.g. peak response of p53 activation occurring at different times post-
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exposure). We performed a time-course experiment on the STHdh striatal neuroprogenitors with 50 µM 
manganese (see Figure 14E,F [for 1, 3, and 24 hour exposures] and Figure 16 [for 1, 3, 6, and 24 hour 
exposures]) and saw a continuous accumulation of phosphorylation of p53(S15) and H2AX(S139) over the 24-
hour period in the control line (STHdhQ7/Q7). The HD line (STHdhQ111/Q111) did not show manganese-induced 
phosphorylation of p53 or H2AX at any of the time points, indicating that the difference in ATM activity 
observed between control and HD lines was not the result of a difference in temporal response patterns. 
Together, these observations demonstrate a manganese-specific deficit in ATM activation in HD not observed 
with other known activators of ATM kinase. 
 
 
Figure 16. Another antibody for phos-p53(S15) corroborates the specificity of HD-dependent manganese 
phenotype. Mouse STHdh neuroprogenitors (Q7 and Q111) were treated identically to Figure 6A,C,E for the In-Cell 
Western assay except using a rabbit polyclonal antibody rather than the monoclonal mouse antibody Figure 6. N=5 wells. 
# is used to indicate significantly different values relative to vehicle-treated cells. For genotype comparisons * < 0.05 and 
*** < 0.001. Bars, mean + 95% CI. 
 
 
Cellular manganese accumulation is diminished in HD neuroprogenitors 
Because the HD-dependent deficit in manganese-induced ATM activation was remarkably selective to 
manganese and because manganese is sufficient to induced ATM activity in cell-free kinase assays, we 
hypothesized that mutant Huntingtin alters intracellular manganese homeostasis (Chan et al., 2000; Z. Guo et 
al., 2010). We have previously reported decreased manganese accumulation in the mouse STHdhQ111/Q111 HD 
striatal lines compared to the control STHdhQ7/Q7 line (Williams, Kwakye, et al., 2010; Williams, Li, et al., 2010). 
However, this phenotype occurred with a significant decrease in manganese-induced cytotoxicity and 
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manganese-induced AKT(S473)  phosphorylation in the mutant cells (STHdhQ111/Q111), phenotypes that we did 
not see in the human neuroprogenitors used in this study (Figures 7A and 9D). To measure intracellular 
manganese content, we used a fluorescence-based assay (CFMEA) that we have previously described (K. K. 
Kumar et al., 2013; Kwakye, Li, Kabobel, et al., 2011). We found that human HD neuroprogenitors 
accumulated significantly less manganese (31% versus control cells, p < 0.01) after a 24-hour manganese 
exposure at 200 µM (Figure 17A). However, this difference between human control and HD neuroprogenitors 
was ~2.5 times smaller than observed in mouse neuroprogenitors (78% reduction of manganese in 
STHdhQ111/Q111 cells versus control cells; Figure 17B). Thus, both human and mouse neuroprogenitors with 
pathogenic alleles of Huntingtin display deficits in net manganese accumulation at concentrations associated 
with deficits in manganese-dependent ATM-p53 signaling. 
 
 
Figure 17. Reduced accumulation of manganese in neuroprogenitors expressing mutant Huntingtin. (A) 
Accumulation of intracellular manganese was quantified in human neuroprogenitors that were exposed for 24 hours to 
manganese by cellular fura-2 manganese extraction assay. For human N = 4 for control (CE-6 and CF-1, twice each) and 
HD (HD70-2 and HD180-4, twice each). (B) The same procedure was performed on mouse STHdh  neuroprogenitors (Q7 
and Q111) with N = 3. For genotype comparisons * for p < 0.05, ** p < 0.01, *** p < 0.001 by t-test. Bars, mean + SEM.  
 
 
Pharmacological equalization of cellular manganese content rescues the ATM-p53 signaling deficit. 
To determine if the differential manganese accumulation in HD is the basis of the differential manganese-
induced ATM activation, we pharmacologically manipulated intracellular manganese content. To this end, we 
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(Waghorn et al., 2009) to alter cellular manganese content in the control and HD STHdh neuroprogenitors. Co-
incubation of the mouse STHdh neuroprogenitors with 10 µM KB-R7943 and 50 µM manganese resulted in 
equivalent manganese accumulation between control STHdhQ7/Q7 and HD STHdhQ111/Q111 lines (Figure 18A, p = 
0.585). Using these conditions to equalize cellular manganese levels, we found that KB-R7943 also equalized 
the phosphorylation levels of p53(S15) and H2AX(S139) between HD and control neuroprogenitors (Figure 
18B,C; p = 0.31 for p53[S15] and p = 0.95 for H2AX[S139]). These data demonstrate that normalizing cellular 
manganese levels mitigates the HD-dependent deficit in manganese-induced ATM target phosphorylation. 
 
	  
Figure 18. Pharmacological equalization of manganese content results in similar p53(S15) phosphorylation. (A) 
Mouse STHdh neuroprogenitors (Q7 and Q111) were treated for 24 hours with manganese (50 µM) with or without the 
NCX inhibitor KB-R7943. Intracellular manganese accumulation was measured by the CFMEA technique. N = 3 
independent experiments. (B,C) The same treatment paradigm was used for In-Cell Western analysis to quantify the 
phosphorylation of p53 and H2AX. N = 4 independent experiments for (B) and N = 3 independent experiments for (C). For 
genotype comparisons * for p < 0.05, ** p < 0.01, *** p < 0.001 by t-test. Bars, mean + SEM. 
 
	  
Discussion 
Our observations demonstrate that a manganese-handling deficit occurs in HD striatal-like neuroprogenitor 
selectively impairing ATM-p53 signaling under low-level (sub-cytotoxic) manganese exposure levels (>85% 
viability; Figure 7) with no detectable caspase-3 or PARP-1 cleavage (Figure 8C,D). We used an ELISA-
based array for 18 cellular signaling events and found that phosphorylation of p53(S15) showed the largest 
response (2.2 fold increase in human; 3.8 fold increase in mouse; Figure 8), and this response was 
significantly reduced in HD neuroprogenitors (~78% decrease in human response [p < 0.001]; 69% decrease in 
mouse response [p < 0.01])(Figure 9B,C). AKT(S473) phosphorylation was also induced by manganese but to 
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a lesser extent (1.2 fold for human and mouse, p < 0.05) and independent of the HD genotype (Figure 9D). 
Manganese-dependent phosphorylation of CHK2(T68) and H2AX(S139), two canonical targets of ATM kinase, 
were also found to be deficient in HD cells (Figure 13A,C,E). DNA damage and oxidative stress induced by 
hydrogen peroxide, two known mechanisms to activate ATM activity, did not show HD-dependent differences 
in the mouse striatal progenitors. DNA-damage resulted in hyper-activation of ATM targets in human HD 
neuroprogenitors (Figures 13B,D,F). Mirroring our findings in the mouse striatal cell line, the human 
neuroprogenitors had a small but significant defect in cellular manganese accumulation relative to control 
(Figure 17A). However, this difference did not result in manganese cytotoxicity (Figure 7A) or manganese-
dependent AKT(S473) phosphorylation differences between control and HD cells (Figure 9D). Combined, our 
results demonstrate an altered manganese biology in HD patient-derived neuroprogenitors and identify a novel 
manganese-responsive cell signaling event, ATM activation, that is impaired in HD. Our data, in both human 
and mouse model systems, support the hypothesis that a manganese homeostatic defect may occur in HD.  
Our data establish ATM-p53 as a major manganese response pathway. Alterations in p53-dependent 
gene expression following manganese-exposure have been observed in a non-human primate model (Guilarte 
et al., 2008; Zhao et al., 2012). Here, we provide evidence for manganese-induced p53(S15) phosphorylation 
by western blot, ELISA, and In-Cell Western assays in both human and mouse neuroprogenitors. Further, this 
signaling pathway was activated more robustly than several other intracellular signaling events assayed. The 
identification of ATM as the upstream manganese-induced kinase of p53 is based on both pharmacological 
inhibition and other established ATM phosphorylation targets (CHK2[T68] and H2AX[S139]). DNA damage and 
oxidative stress have both been shown to activate ATM, but unlike manganese-dependent ATM activation, 
DNA damage and hydrogen peroxide had the same or greater response in HD neuroprogenitors compared to 
controls consistent with previous reports on p53 in HD model systems (Banin et al., 1998; Canman et al., 1998; 
Z. Guo et al., 2010). Among the metal ions tested, only cadmium induced ATM activation to a similar 
magnitude as manganese. However, unlike manganese, cadmium is a known DNA damaging agent at 
micromolar concentrations providing a clearly established route to ATM activation (Dally & Hartwig, 1997). 
Manganese, on the other hand, is known to activate ATM phosphorylation of p53(S15) in purified kinase 
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activity assays in the absence of DNA (Chan et al., 2000; Z. Guo et al., 2010). Thus, our data strongly suggest 
manganese activates ATM via a mechanism independent of DNA damage. Additionally, our results do not 
support a mechanism via direct redox cycling (Fenton reaction) because many of the other metals, which had 
minimal effects on ATM activity, are known to be more redox active than manganese (e.g. copper). As neither 
a DNA damage nor oxidative stress mechanism clearly explains the manganese-dependent ATM activation, 
we propose that manganese activates ATM via a novel mechanism. Our data demonstrate that manganese 
mediates the activation of ATM kinase activity at neurologically relevant concentrations (50-200 µM) in living 
cells (Bowman & Aschner, 2014), much lower than the 5-10 mM used in previously published cell-free purified 
kinase assays (Chan et al., 2000; Z. Guo et al., 2010).  
The HD dependent deficit in manganese induced ATM-p53 activation is one of many examples 
implicating this pathway with HD pathophysiology. Previous work has shown increased p53 accumulation and 
phosphorylation in HD patient and mouse brains as well as HD cell lines under basal conditions, while 
knockdown of p53 can ameliorate both mitochondrial and behavioral HD phenotypes (B.-I. Bae et al., 2005; X. 
Guo et al., 2013). Possible direct interactions between mutant Huntingtin and both p53 and ATM have also 
been reported ((B.-I. Bae et al., 2005; Ferlazzo et al., 2013; Steffan et al., 2000). Both p53 and ATM 
phosphorylation have been reported to be elevated in an HD iPSC model (Jung-Il et al., 2012). This pathway 
was also hyper-activated by DNA damage in our HD neuroprogenitors, mirroring the published findings of 
camptothecin (a DNA damaging agent) treatment of HD muscle cells (Ehrnhoefer et al., 2014).  Genetic 
variation in the TP53 gene (which encodes p53 protein) accounts for ~13% of age-of-onset variability in HD not 
accounted for by the CAG repeat length (Chattopadhyay et al., 2005). The pro-apoptotic function of activated 
p53 is its best characterized biological role; however, at low levels of activation, p53 transcriptional activity 
plays a largely pro-survival role by up-regulating genes involved in energetic balance, oxidative defense and 
metabolic state (Helton & Chen, 2007). The HD-dependent alterations in p53 responsiveness to a non-lethal 
stressor could provide a mechanism for the age-dependent degeneration seen in HD. Namely, the 
accumulation of cellular damage over time due to insufficient neuroprotection by the manganese-dependent 
ATM-p53 pathway.  
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Our data suggest that mutant Huntingtin impinges on the ATM-p53 response to manganese exposure 
by altering manganese transport/homeostasis. We found lower cellular manganese content in the HD human 
ISL1+ neuroprogenitors than control cells following low-level exposures (Figure 13A). Equalizing cellular 
manganese content in HD and control cells by pharmacologically blocking manganese efflux (Waghorn et al., 
2009) eliminated the differential response in p53 phosphorylation, providing strong evidence that the deficit in 
manganese-induced ATM activation in HD cells was dependent on a manganese-handling deficit. Remarkably, 
the magnitude of the deficit in the ATM-p53 signaling pathways in mouse and human HD models is similar 
despite the substantially stronger manganese accumulation deficit in the mouse model system. One potential 
explanation could be differences in compartmentalization of intracellular manganese between the mouse and 
human models. Manganese has been indicated to accumulate primarily in the nucleus of neurons where a 
majority of ATM protein is localized (Kalia et al., 2008; Morello et al., 2008).  
Epidemiological studies indicate a significant role for environmental factors in HD progression (Wexler, 
2004). The defect we observe in manganese-handling/homeostasis in HD patient derived neuroprogenitors 
substantiates previous reports of reduced accumulation of manganese in both mouse striatal cell models of HD 
and the striata of manganese-exposed Tg-YAC128Q HD model mice, as well as altered manganese and iron 
localization in HD patient brains (H Diana Rosas et al., 2012; Williams, Kwakye, et al., 2010; Williams, Li, et al., 
2010). Decreased cellular manganese in HD could explain at least some HD pathogenic mechanisms. For 
example, decreased activity of manganese-dependent enzymes, including superoxide dismutase (MnSOD), 
arginase, glutamine synthetase, and pyruvate carboxylase could contribute to the oxidative stress, altered 
neuronal energetics, and excitotoxicity pathological phenotypes reported in HD (Bowman, Kwakye, Herrero 
Hernández, et al., 2011). Further, differential manganese nutritional status of patients could be an important 
modifier of disease progression. Manganese deficiency is known to alter glutamate cycling, the urea cycle, 
insulin signaling, and cellular energetics; all of these biochemical pathways are dependent on manganese-
dependent enzymes and have been shown to be dysfunctional in Huntington’s disease models (Chiang et al., 
2007; Lievens et al., 2001; Podolsky et al., 1972; Seong et al., 2005). In conclusion, these findings suggest the 
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possibility that alterations in brain manganese homeostasis may contribute to HD pathophysiology, which may 
open new therapeutic opportunities. 
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CHAPTER III 
 
GENOMIC INSTABILITY IN HUNTINGTON’S DISEASE CELLS MAY RESULT 
FROM NUCLEAR MANGANESE DEFICIENCY  
 
Introduction 
Huntington’s disease neuropathology results from cell death of neurons primarily in the caudate and putamen 
of the basal ganglia. Although this cell death has been well-characterized, the route by which mutant huntingtin 
expression leads to cell death is not well understood. Elevated phosphorylation of DNA damage signaling 
pathway markers such as p53 is a hallmark of HD (B.-I. Bae et al., 2005; Trettel et al., 2000). Mutant huntingtin 
expressing cells have also been shown to be radiosensitive to X-rays suggesting a potential DNA damage 
repair defect (Moshell et al., 1980). Recent studies have shown altered DNA repair kinetics of important double 
strand break (DSB) repair proteins, such as Ku70 and MRE11, and binding of mutant huntingtin to important 
DNA damage signaling proteins, p53 and ATM (Enokido et al., 2010; Ferlazzo et al., 2013; Moshell et al., 
1980; Steffan et al., 2000). Further evidence for altered response to DNA damage and repair is that HD 
patients have a significantly decreased risk of nearly all forms of cancer compared to control individuals 
(Sørensen et al., 1999).  
We discovered increased genomic instability as evidenced by abnormalities in karypotype analysis in 
induced pluripotent stem cell (iPSC) lines generated from patients with Huntington’s disease as well as 
elevated DNA damage signaling in HD iPS cells and mouse striatal cells. Previously, our lab has shown a 
drastic decrease in intracellular manganese levels in HD cells. Manganese is a necessary or putative cofactor 
for several important proteins involved in DNA damage repair (e.g. MRE11 and ATM). We believe that our data 
suggesting decreased nuclear manganese in HD could provide a coherent mechanism for increased DNA 
damage and DNA damage dependent signaling in HD patients and model systems by decreasing the activity of 
these enzymes. Indeed, supplementation of manganese can restore elevated p53 phosphorylation in HD cells 
to control levels.  
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Results and Discussion 
 
Increased genomic instability in HD cells 
Our lab has generated induced pluripotent stem cell (iPSC) lines from control subjects and patients with 
neurodegenerative diseases including juvenile Huntington’s disease (HD) (Chapter II). Because iPSC (and 
hESC) lines are known to have frequent genomic abnormalities (Draper et al., 2004; Mayshar et al., 2010), a 
detailed karyotype analysis (20 metaphase spreads) was performed on each clonal line to ensure genomic 
integrity. We observed a strikingly high number of HD iPSC lines with genomic abnormalities (10/29 lines from 
5 patients) (Figure 19). This observation was made all the more stark when we did not identify a single 
genomic abnormality in any of our control lines (0/13 lines from 4 control subjects). Using a binary logistic 
regression, disease state was a significant predictor of genomic instability (p = 0.0017). Furthermore, the 
length of the CAG repeat was also a significant predictor of genomic instability in the iPSC lines (all controls 
were set to 20 CAG repeats) with p = 0.0025. 
 
 
Figure 19. HD iPSC lines have greater propensity for genomic abnormalities than control lines. Left: Control lines 
from 4 individuals (13 total lines) and HD lines from 5 patients (29 total lines) were analyzed by G banding for 
chromosomal abnormalities. Lines with at least 1 abnormality (deletion, inversion, trisomy etc) out of 20 cells counted 
were considered abnormal. Right: The abnormalities are depicted on a karyogram. Additional chromosomal material is 
depicted as solid bars, loss as hashed bars, and translocations as lines connecting the translocated regions. 
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iPSC Line Patient Phenotype Abnormal/Total Passage # Nature of Abnormalities 
CA-11 Control 0/20 ?  
CA-24 Control 0/20 9  
CA-26 Control 0/20 6  
CA-30 Control 0/20 8  
CC-1 Control 0/20 7  
CC-2 Control 0/20 6  
CC-3 Control 0/20 6  
CC-5 Control 0/20 7  
CD-2 Control 0/20 6  
CD-3 Control 0/20 6  
CD-10 Control 0/20 9  
CD-12 Control 0/20 9  
CE-6 Control 0/20 6  
HD35-2 HD 20/20 4 i(5)(p13q32) 
HD35-5 HD 0/20 4  
HD35-7 HD 0/20 4  
HD35-9 HD 0/20 4  
HD57-1 HD 0/20 4  
HD57-4 HD 0/20 4  
HD57-6 HD 0/20 4  
HD57-7 HD 0/20 4  
HD57-15 HD 0/20 4  
HD58-1 HD 2/20 7 47, X, +12 
HD58-1 -shRNA p53 HD 0/20 6  
HD58-3 HD 0/20 6  
HD58-13 HD 4/20 17 i(20)(q10) [2]; idic(q13.3) [2] 
HD58-19 HD 0/20 10  
HD58-20 HD 0/20 7  
HD58-21 HD 5/20 10 47, XY, +12 
HD58-31 HD 0/20 6  
HD58-34 HD 0/20 6  
HD70-2 HD 0/20 ~14  
HD70-5 HD 1/20 ~15 47, XX, +12 
HD70-11 HD 0/20 8  
HD180-1 HD 20/20 ~15 del(13)(q22q32)* 
HD180-1 -shRNA p53 HD 20/20 6 del(Y)(q12) 
HD180-3 HD 9/20 ~15 47, XY, +18 
HD180-4 HD 0/20 6  
HD180-6 HD 0/20 11  
HD180-10 HD 20/20 6 del(13)(q22q32)*,add(21)(q22),r(21)(p11.2q22) 
HD180-14 HD 20/20 6 46,X,add(Y)?(q11.22) 
HD180-16 HD 20/20 6 46,XY,t(1;15)(p10;p10) 
 
Table 1. Karyotype data for control and HD iPSC lines. 20 metaphase spreads were analyzed for each line. Lines are 
deemed abnormal if they contain one inversion, deletion, or translocation in one or more cell. They are also considered 
abnormal if they have two or more cells with the same trisomy or monosomy, or 1 cell with a trisomy that commonly 
occurs in iPSC culture (eg. trisomy 12). Abnormal lines are colored in red. Abnormalities are listed by accepted 
nomenclature with brackets around the number of cells with a particular abnormality if more than one occurs in a given 
line. * If an abnormality was seen in subsequent fibroblast analysis, the iPSC line was considered normal. 
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The HD iPSC genomic abnormalities were from many different classes including trisomies (4), translocations 
(2), deletions (1), additions (3), inversions (2), isodicentrism (1), and ring formation (2) (Table 1). The most 
common abnormality was trisomy 12 (3), which is known to occur frequently in iPSC lines because the 
increased expression of important pluripotency genes (ie. Nanog) found on this chromosome provides a growth 
advantage for these cells (Mayshar et al., 2010). The HD chromosomal abnormalities identified are depicted on 
a karyogram in Figure 19 and listed in Table 1.  
These abnormalities could have arisen in the original fibroblast lines and not during the reprogramming 
or iPSC state. Therefore, we performed karyotype analysis on two control and three HD fibroblast lines. 
Instead of our normal 20 metaphase spreads, we performed 100 for each fibroblast lines because the 
abnormalities’ observed in the iPSC lines could have arisen from rare events in the fibroblasts that provided an 
advantage in the reprogramming process. Each line had a similarly low level of genomic abnormalities (1-2 
cells out of 100) in both the control and HD lines (HD58 and HD70), except for HD180 (Table 2). This fibroblast 
line contained 49 abnormal cells out of 100 with 3 different abnormalities of all different classes (deletion [3 
cells], translocation [4 cells], and addition [42 cells]). Although all of the fibroblast lines contained at least a low 
level of genomic structure variation, only one abnormality identified (del(13)(q22q32) from HD180) was 
identified in any of the iPSC lines (HD180-1 and HD180-10). HD180-1 was considered as normal in the iPSC 
data analysis in Figure 19 because the abnormality arose in the fibroblast culture, and HD180-10 was 
considered abnormal because it contained 2 other abnormalities that did not occur in the fibroblast culture. 
These results indicate that the vast majority of iPSC genomic abnormalities arise during the reprogramming 
process or in the iPSC cell state. We have also shown that HD patient cells are vulnerable to genomic 
instability at both the iPS (all HD lines) and fibroblast (HD180) cell states. ‘ 
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Fibroblast Line Abnormal/Total Passage # Nature of Abnormalities 
CA 1/100 7 del(2)(q33) 
CF 1/100 < 20 add(4q) 
HD58  2/100 7 45, X [2] 
HD70  2/100 14 del(8)(q10) [1]; del(18)(p10) [1] 
HD180 49/100 17 
del(13)(q22q32)[3]; 
t(3;14)(p13;q11.2)[4];add(4)(q23)[42] 
 
Table 2. Only HD180 fibroblasts have a greater rate of abnormal karyotypes compared to controls. 100 metaphase 
spreads from each fibroblast line were analyzed for chromosomal abnormalities.  
 
Subsequent experimental use of HD iPSC lines would be confounded if the HD propensity for genomic 
abnormalities occurs frequently in the stable iPS cell state. Lines would need to be analyzed frequently to 
ensure genomic integrity. To test for this possibility, we aged several control and HD lines to between 26-33 
passages (an average of 16 additional passages from the original analysis). Both control (1/3) and HD (2/4) 
lines demonstrated a low frequency of abnormalities (average of 1.6 out of 100) not observed in the line during 
the original analysis (Table 3). Although not conclusive, these data suggest a similar slow accumulation of 
genomic abnormalities in both control and HD cells (p= 0.6576 by binary logistic regression).  
 
iPSC Line Patient Phenotype Abnormal/Total Passage # Nature of Abnormalities 
CA-30 Control 9/100 26(+18) i(20)(q10) [8] 
CF-3 Control 0/100 26 (+20)  
CF-3 Control 0/100 32 (+24)  
HD58-19 HD 0/100 26 (+16)  
HD70-2 HD 0/100 26 (+12)  
HD70-2 HD 2/100 32 (+18) +12 [1], +22 [1] 
HD70-5 HD 3/100 33 (+7) +12 [2], i(20)(q10) [1] 
 
Table 3. Euploidic HD iPSC lines accumulate abnormalities at the same rate as controls. The iPSC lines were aged 
in culture fro 7-24 passages greater than when original karyotyping was performed (see Table 1). 100 metaphase spreads 
from each fibroblast line were analyzed for chromosomal abnormalities.   
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HD cells show increased DNA damage signaling  
Although both hES and iPSC models of Huntington’s disease have been reported by several groups, genomic 
instability has not been previously reported. Here we report the generation of HD iPS lines using p53 siRNA 
alongside the typical reprogramming factors (Okita et al., 2011). Since p53 is known to suppress iPS 
generation, p53 knockdown via siRNA is used to increase reprogramming efficiency (Hong et al., 2009). This 
efficiency comes at a cost by decreasing the genomic integrity of iPSC clonal lines generated with p53 siRNA 
(Marión et al., 2009). Interestingly, elevated p53 signaling is one of the most consistent phenotypes across HD 
disease models (B.-I. Bae et al., 2005; X. Guo et al., 2013; J. L. Illuzzi et al., 2011; Jung-Il et al., 2012; Trettel 
et al., 2000). Many of these studies have also shown concurrent elevation of either H2AX or ATM 
phosphorylation, indicating an ATM kinase dependent pathway activation of p53.  Therefore, elevations in 
ATM-p53 pathway could indicate an increase in DNA damage in HD cells under basal conditions. We explored 
whether p53(S15) and H2AX(S139) phosphorylation were increased in our HD iPS lines as well as the mouse 
STHdh striatal neuroprogenitor model. Using the HD iPS cells, we performed p53 western blots under basal 
conditions and with the DNA damaging agent, neocarzinostatin, which is known to increase phosphorylation 
and accumulation of p53. We show a significant increase in the phosphorylation of p53 at serine-15 and total 
p53 expression in HD iPS cells compared to controls (Figure 20A-B). DNA damage 
 
 
Figure 20. HD iPS cells have elevated basal and DNA damage dependent ATM-p53 signaling. Control and HD iPS 
cells were treated for 1 hour with DNA damaging agent, neocarzinostatin. Western analysis was performed for 
phosphorylated p53 at serine 15 (A), total p53 (B), and phosphorylated histone H2AX at serine 139 (C).  N = 6 for control 
(CA-11 = 2,  CF-1 = 2, CF-2 = 1) and 6 for HD (HD58-19 = 3, HD70-2 = 1, HD180-4 = 2). Bars = SEM. P value is 
calculated via 2-way RM-ANOVA (A,B) or t test (C).  
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via neocarzinostatin increased p53 phosphorylation and total protein in both cell lines at concentrations that did 
not significantly decrease cell viability (Figure 21). The apparent differences between HD and control cells at 
each concentration of neocarzinostatin in Figure 20 was the exact same fold difference as the untreated 
samples. Additionally, the ratio of phosphorylated p53 total was the same for both lines under basal or treated 
conditions. This is expected because phosphorylation of p53 inhibits its degradation by the ubiquitin-
proteosome system. The HD iPS cells also showed basal elevation of H2AX(S139) phosphorylation (Figure 
20C). This ATM-dependent phosphorylation is often used as a surrogate measurement for DNA damage (Paull 
et al., 2000). 
 
 
Figure 21. Control and HD iPS cells do not show a significant difference in neocarzinostatin mediated cell 
viability loss. Control and HD iPS cells were treated for 1 hour with neocarzinostatin followed by 23 hours of recovery 
time. The MTT assay was then used to quantify cell viability. N = 7 for control (CD-2 = 3, CE-6 = 1, CF-1 = 3) and N = 8 
for HD (HD58-19 = 2, HD70-2 = 3, HD180-4 = 3). Points = mean ± SEM. 
 
The mouse STHdhQ111/Q111 striatal cells also showed an increase in p53(S15) and H2AX(S139) phosphorylation 
under basal conditions (Figure 22A). These differences were not shown in Chapter II because they interfere 
with assessment of the relative effects of manganese on p53 signaling; therefore, we normalized each line to 
its vehicle-treated control in that chapter.  
Interestingly, human ISL1+ HD neuroprogenitors show a decrease in p53 and H2AX phosphorylation 
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lack of manganese in the Islet1+ cell medium. The other model systems do contain manganese in there growth 
medium; therefore, any possible connection between basal p53 phosphorylation and manganese uptake 
differences would not be apparent in the Islet1+ cells. The elevations in DNA damage signaling in the other cell 
models likely indicate underlying DNA damage or repair problems caused by the expression of mutant 
Huntingtin, which may also explain the increased rate of genomic instability seen during reprogramming of HD 
patient fibroblasts into hiPSCs (Figure 19). 
 
 
Figure 22. Elevated p53 and H2AX phosphorylation in untreated HdhQ111/Q111 cells but not in HD human 
neuroprogenitors. In-Cell Western assay was used to determine the level phosphorylation of ATM kinase targets p53, 
H2AX, and CHK2 in HdhQ7/Q7  and HdhQ111/Q111 striatal cells (A) and human neuroprogenitors (B). N = 4 for each. Bars = 
SEM. * for p < 0.05, ** for p < 0.01, and *** for p < 0.001 by t-test. 
 
DNA damage and repair problems in HD cells have been previously identified. Expression of mutant 
Huntingtin can cause increased DNA DSBs in cells and mouse brain (Enokido et al., 2010; J. Illuzzi et al., 
2009; J. L. Illuzzi et al., 2011). Evidence from one HD model, the R6/2 mouse, suggested increased DNA 
oxidation as key HD disease mechanism (Bogdanov et al., 2001; De Luca et al., 2008). However, studies 
measuring oxidized DNA in HD patient postmortem brains have provided conflicting results (Alam et al., 2000; 
Browne et al., 1997; Polidori et al., 1999). Chromosomal abnormalities can occur by DNA damage; DNA 
double-stranded breaks (DSBs) can be erroneously repaired to cause translocations, other rearrangement 
events (ie deletions, inversions), and possibly aneuploidy. Huntington’s disease cell and animals models have 
shown increased DNA-damage and DNA-damage induced signaling responses (ie. ATM-p53) (B.-I. Bae et al., 
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2005; Bogdanov et al., 2001; De Luca et al., 2008; Ehrnhoefer et al., 2014; Enokido et al., 2010; J. Illuzzi et al., 
2009; J. L. Illuzzi et al., 2011; Jung-Il et al., 2012; Trettel et al., 2000). 
 
No evidence of centrosome amplification in HD iPS cells 
Alternatively, these genomic aberrations, particularly aneuploidy, can arise from dysregulated chromosomal 
segregation during cell division (Ganem et al., 2009). Huntington’s disease cells have shown disruption to 
centrosomes and mitotic spindles that could potentially lead to misappropriation of chromosomes during 
mitosis (Godin et al., 2010; Keryer et al., 2011; Sathasivam et al., 2001). One of these studies identified 
increased centrosomal amplification in mouse and HD fibroblasts (Sathasivam et al., 2001). This amplification 
resulted in cells containing more than two centrosomes leading to multipolar mitoses. Having greater than 2 
poles segregating chromosomes leads to misappropriation and aneuploidy. However, this study did not provide 
quantitative data about the rate of centrosome amplification between the two disease groups.  
We quantified cells with supernumerary centrosomes (> 2) in both fibrobasts and iPSCs by pericentrin 
immunolabeling. As expected, actively dividing cells were more likely to be multipolar because under normal 
circumstances duplication of the centrosome happens just prior to cell division. The rate of mulitpolar cells was 
much higher in iPS cells compared to fibroblasts (Figure 23A). This increased chromosomal amplification has 
been described previously in human embryonic stem cells (Holubcová et al., 2011). When we further 
characterized the number of supernumerary centrosomes by genotype, we found no statistical difference 
between control and HD cell lines (Figure 23B). Therefore, we do not believe that centrosomal amplification is 
a significant process in the selective HD dependent genomic instability. 
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Figure 23. Mutant huntingtin does not alter the incidence of multipolar cells. (A) Human fibrobasts and iPS cells 
were stained pericentrin, a protein marker of centrosomes. 20 mitotic cells for each experiment were identified by Hoechst 
DNA stain with clear chromosomes. Cells were then scored as either multipolar (3+ centrosomes identified by pericentrin) 
or normal (1-2 centrosomes. (B) Control and HD iPS cells were also analyzed for centrosome amplification. N=6 for each 
bar. Bars = SEM. P value by t-test.  
 
 
Decreased manganese levels in detergent permeable cellular compartments of HD mouse striatal cells 
We have previously described decreased manganese accumulation in HD human and mouse neuroprogenitors 
as well as selectively in HD mouse striata upon manganese exposure. However, manganese-dependent 
phosphorylation events varied in the level of HD dependent response deficit. Primarily, nuclear p53 and H2AX 
were almost completely unresponsive to manganese-dependent phosphorylation in mutant cells while AKT (a 
mainly cytoplasmic protein) phosphorylation in humans was not different between controls and mutants 
(Chapter II, Figure 9). This led to the hypothesis that the deficit in manganese accumulation was due to 
reduced nuclear manganese levels. The nucleus has already been identified as a major site of manganese 
accumulation in manganese exposed neurons and contains the highest level of manganese in both 
manganese exposed and unexposed neurons and astrocytes (Kalia et al., 2008; Morello et al., 2008). 
Unfortunately, our previously published technique (CFMEA) for measuring manganese accumulation only 
measured total cellular manganese levels (Kwakye, Li, & Bowman, 2011; Kwakye, Li, Kabobel, et al., 2011), 
but using this same technique with different detergents, we are now able to potentially assess cytoplasmic, 
nuclear, and mitochondrial manganese levels.  
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The CFMEA was performed without Triton X-100 detergent to assess both residual extracellular 
manganese after washes as well as any readily released manganese from the cell via the concentration 
gradient (Figure 24A). We were surprised by the high concentration detected in these wells without a 
significant difference between Q7 and Q111 cells. We also replaced Triton X-100 (0.1%) with the non-ionic 
detergent, digitonin (0.001%) (Figure 24B). This replacement had no effect on manganese dependent fura-2 
quenching, key to the CFMEA assay (Figure 24F). Digitonin is known to permeabilize the plasma membrane 
but not the mitochondrial membrane or other non-cholesterol containing membranes while Triton X-100 does. 
The CFMEA was also performed with our standard 0.1% Triton X-100 (Figure 24C). As shown in Figure 18, 
KB-R7943 also ameliorated the HD-dependent deficit in manganese accumulation. Here we show that this 
occurs in both the digitonin and TX-100 permeable fractions (Figure 24B,C,E). KB-R7943 treatment also 
significantly increased the manganese quantified in the detergent free sample (Figure 24A, p = 0.0146). 
 
 
Figure 24. Digitonin permeable fraction has the greatest reduction in Q111 compared to Q7 cells. A-C The CFMEA 
managanese assay was performed with PBS, digitonin, or Triton X-100, and the resulting manganese concentration in the 
lysate was calculated. D-E Cell fraction concentrations were determined by subtraction for cytoplasmic (PBS), nuclear 
(digitonin – PBS), and mitochondrial (Trition X-100 – digitonin). N = 3 independent experiments with 2-4 biological 
replicates each. Bars = SEM.  
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We have confirmed that both digitonin and Triton X-100 (but not detergent-free PBS) permeabilize the plasma 
membrane and the nuclear envelope of the Hdh mouse striatal cells as measured by the fluorescence of a 
non-membrane permeable double-strand DNA dye, pico green (Figure 25). Therefore, by subtracting the 
calculated manganese concentration of the PBS from the digitonin permeabilized cells, we are able to estimate 
the amount of manganese in the nucleus or other digitonin permeable compartments. Likewise, by subtracting 
the digitonin concentration from the Triton X-100 concentration, we can estimate the manganese found in 
digitonin resistant compartments. However, the large difference in overall picogreen fluorescence between the 
TritonX-100 and digitionin may suggest that the nuclear envelope is permeable to picogreen but is completely 
dissolved with TritonX-100 allowing much more intercalation of the dye with DNA.  
 
 
Figure 25. Digitonin and Triton X-100 permeabilize the plasma membrane and nuclear envelope. Kinetic reads 
were taken of well containing PBS and double-stranded DNA dye, picogreen. Detergents digitonin and Triton X-100 were 
also added to some wells. The increase in signal in the detergent well but not in the PBS wells demonstrates plasma 
membrane and nuclear envelope permeabilization (pico green is membrane impermeable). N = 8 wells for Triton X-100 
and PBS (4 Q7 and 4 Q111) and N = 16 wells for digitonin (8 for Q7 and 8 for Q111).  Error = SEM.  
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sequestration of manganese by proteins that which use manganese as a cofactor or by divalent cation binding 
to the phosphate backbone of nuclear DNA are also possible. In any case, the genotypic difference in nuclear 
manganese accumulation is severe as we are unable to detect any nuclear manganese in the Q111 cell line 
with our current techniques. 
We believe altered manganese homeostasis could underlie many of the pathological phenotypes in 
Huntington’s disease patients (Chapter I). Nuclear manganese deficiency could also potentially lead to 
genomic instability because manganese is an important co-factor for DNA replication and repair enzymes 
(Frank & Woodgate, 2007; Hays & Berdis, 2002; Hopfner et al., 2001; Trujillo et al., 1998). For example, 
MRE11 a necessary part of the DNA repair complex, MRN, has a di-manganese binding pocket, and the 
presence of manganese is necessary for its nuclease activity, which cannot be substituted by magnesium or 
calcium (Hopfner et al., 2001; Paull & Gellert, 1998; Trujillo et al., 1998). This activity is necessary for proper 
repair of double-stranded DNA breaks (DSBs) via homologous recombination; however, nuclease activity-dead 
MRE11 mutants still undergo MRN complex binding to DSBs and MRE-11 dependent ATM phosphorylation 
(Limbo et al., 2012).  
Additionally, manganese content has been found to regulate the activity of translesion DNA polymerase 
activity (e.g. DNA polymerase iota) (Hays & Berdis, 2002) . Translesion polymerases allow for replication in 
DNA with damage lesions increasing cellular tolerance for DNA damage (Waters et al., 2009). Reduced activity 
due to loss of manganese content may be a reason for increased radio-sensitivity and oxidative stress 
sensitivity in HD cells (Browne et al., 1999; Moshell et al., 1980). Interestingly, translesion polymerases have 
high error rates; in fact, DNA polymerase iota has ~ 10,000 times grater rate of single base substitution 
compared to non translesion eukaryotic polymerases (McCulloch & Kunkel, 2008). Therefore, manganese-
dependent increases in activity may be a mechanism for manganese-dependent increases in mutagenesis, a 
result of high manganese exposure (Beckman et al., 1985). Reduced translesion polymerase activity in HD 
could also be a potential mechanism for reduced risk for all cancers in HD patients (Sørensen et al., 1999). 
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Manganese exposure rescues the elevated p53 phosphorylation in HD cells 
As we showed earlier, the HD model Q111 cells had elevated p53 phosphorylation. When we exposed these 
cells to 50 µM manganese and measured p53 phosphorylation at 1 and 3 hours, we found that at both time 
points the elevated p53 phosphorylation returned to statistically the same levels as untreated Q7 cells (Figure 
26A). We did not see the same effect on H2AX phosphorylation (Figure 26B). This may suggest two different 
kinases are responsible for the elevated phosphorylation of these two proteins. We also did not see the same 
effect in the human Islet1+ cells since they did not have elevated basal p53 phsophorylation (Figure 22B and 
data not shown).  
 
  
Figure 26. Manganese exposure returns Q111 to the same level of p53 but not H2AX phosphorylation seen in Q7. 
In-cell western was used to quantify phosphorylation of p53 at serine 15 (A) and H2AX at serine 139 (B) in the HdhQ7/Q7 
(Q7) and HdhQ111/Q111 (Q111) cells after various times of manganese exposure. All values were normalized within 
experiment to the vehicle treated (0 hour) Q7 control cells. N = 3 in (A) and 4 in (B). Bars, mean ± SEM. For genotype 
comparisons, * for p < 0.05, ** for p < 0.01, and *** for p < 0.001 by two-way ANOVA with Sidak’s post-hoc analysis. N = 3 
independent experiments. 
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nuclease function could be restored leading to reduced ATM phosphorylation and subsequent p53 
phosphorylation. This is only possible if p53 phosphorylation dynamics are significantly faster than those of 
H2AX since we do not see the same rescue of its elevated basal phosphorylation (Figure 26B). 
 
Conclusions and Future Directions 
We can conclude several important findings from these data. 1.) HD iPS cells have increased genomic 
instability and DNA damage signaling. 2.) The HD dependent cellular manganese deficiency is greatest in 
digitonin permeabilized compartments including but not limited to the nucleus. 3.) Manganese can return p53 
phosphorylation levels in HD to control levels in 1 hour in the STHdh model system presumably due to rescue 
of manganese dependent enzyme activity. 
The necessary experiments needed to conclusively connect manganese deficiency, DNA damage 
signaling, and genomic instability should center around the activity of manganese dependent enzymes, MRE11 
and polymerase iota. We are not yet aware of an in situ activity assay for polymerase iota, but there are some 
for MRE11. When double-stranded DNA breaks occur, the MRN complex binds to these site causing a 
dispersed nuclear staining via MRE11 immunofluroescence (Mirzoeva & Petrini, 2001). As repair progresses 
MRE11 foci give way to Rad51 foci, by measure the rate of pattern change of these two protein foci after DNA 
damage, the rate of DNA repair can be indirectly assessed. In fact, MRE11 foci retention has already been 
shown in one HD model (Ferlazzo et al., 2013).  
 Additionally, DNA damage and repair kinetics can be measured directly by pulsed-field gel 
electrophoresis or indirectly by the Comet method. In short, pulsed-field gel electrophoresis uses high voltage 
pulses to pull large genomic DNA fragments into smears in a gel lane. By measuring the relative amounts of 
DNA in the smear, the relative DNA damage and repair rates can be assayed between different samples 
(Collins, 2004). The comet assay uses single-cell gel electrophoresis to pull loops of DNA out of the lysed 
nucleus. The more DNA damage, the more unwound the DNA is from its histones allowing for longer loops. 
Therefore, measuring the length and intensity of the tails is an indirect measure of DNA damage(Ager et al., 
1990). 
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CHAPTER IV 
 
MANGANESE ACCUMULATION DEFICIENCY IN HUNTINGTON’S DISEASE MAY RESULT FROM LOSS 
OF Na+/Ca2+ EXCHANGER EXPRESSION  
 
 
Introduction 
Huntington’s disease human and mouse cell lines as well as mouse striata have reduce manganese 
accumulation compared with wild type controls (Williams, Kwakye, et al., 2010) (Chapters 2 and 3). Although 
Huntington’s disease models have previously been shown to have altered iron and calcium homeostasis 
(Chapter 1), the mechanisms behind the alterations in these divalent metal cations does not explained the 
apparent alterations in manganese homeostasis (Williams, Kwakye, et al., 2010). In Figure 18, I showed that 
the drug KB-R7943 normalizes the amount of manganese taken up in HD model Q111 striatal cells to control 
levels with minimal effect on the Q7 control cells. Therefore, we believed that the target of this drug plays an 
important role in the etiology of the manganese-handling deficit in mutant huntingtin expressing cells. 
KB-R7943 is known to be an inhibitor of the sodium-calcium exchanger (NCX) (Iwamoto & Shigekawa, 
1998). The three NCX genes encode for ion antiporters that rely on Na influx down the concentration gradient 
to propagate Ca efflux that is vital for the normal functioning of cells (Niggli & Lederer, 1991). These antiporters 
also work in the “reverse” mode in which calcium is pumped into the cell and sodium is released (Matsuda et 
al., 1997). To our knowledge, manganese transport via NCX has not been investigated in an in vitro model; 
however, many lines of evidence point to NCX transporting manganese. NCX is a particularly important protein 
in cardiac function, and manganese is often used as a calcium surrogate given its divalency, similar ionic 
radius, and ability to be detected by MRI (Y. Chen et al., 2012; Waghorn et al., 2009). Two NCX inhibitors KB-
R7943 and SEA0400 have been shown to increase manganese concentration in heart tissue as measured by 
manganese-enhance MRI (Y. Chen et al., 2012; Waghorn et al., 2009). Manganese and many other divalent 
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metals have also been shown to inhibit radio-labeled calcium uptake through the NCX protein potentially via 
competition for the channel (Iwamoto & Shigekawa, 1998). In this study, manganese inhibition of calcium 
uptake showed specificity in these studies for NCX1 and NCX2 over NCX3. Although we originally 
hypothesized that KB-R7943 normalized manganese levels by blocking excess efflux for the HD Q111 cells, 
we found that it actually normalized the expression of NCX1, the most highly expressed NCX in this cell line 
and that KB-R7943 increased its expression. 
 
Results and Discussion 
We have previously identified a severe deficit in manganese accumulation in the HD murine model HdhQ111/Q111 
(Q111) immortalized cell line compared to control HdhQ7/Q7 (Q7) (Williams, Li, et al., 2010). We also discovered 
that 24 hours of co-incubation of the sodium calcium exchange inhibitor, KB-R7943, and manganese resulted 
in the same manganese accumulation between the two genotypes (control and HD) (Figure 27A). We 
hypothesized that the Q111 cell line had excess manganese efflux via NCX that was blocked by the inhibitor. 
However, when we performed the same experiment for only 3 hours, we saw same reduction in Q111 cells but 
no effect of the KB-R7943 (Figure 27B). 
 
 
Figure 27. KB-R7943 but not SEA0400 normalizes manganese uptake at 24 but not 3 hours. Cells were exposed to 
either 50 µM manganese for 24 hours in basal medium (DMEM + 10 % FBS) (A) or to 125 µM manganese for 3 hours in 
HBSS (B) with DMSO, 10 µM KB-R7943 (KBR), or 10 µM SEA0400.  Statistical comparisons between bars was 
performed by two-way ANOVA with LSD post-hoc test with * for p < 0.05 and *** for p < 0.01. N = 2 for (A) and 4 for (B). 
Bars, means + SEM. 
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Additionally, the more specific NCX inhibitor, SEA0400, does not significantly affect manganese accumulation 
at either time point. These data suggest that KB-R7943 must be altering gene expression, or some other long-
term effect, rather then an immediate, direct blockade of the NCX channel.  
We, therefore, investigated the expression level of the three mammalian NCX isoforms: NCX1, NCX2, 
and NCX3. All three have been shown to be expressed in brain tissue (Canitano et al., 2002). Using 
quantitative RT-PCR, we found that only NCX1 and NCX3 expression could be detected and that NCX1 was 
expressed ~60 times greater than NCX3 based on CT values. NCX1 expression was significantly diminished in 
Q111 cells compared to Q7 by approximately 15 fold, and expression was unaffected by manganese exposure 
(Figure 28A). NCX3 expression was also reduced in Q111 by approximately 40% compared to Q7 (Figure 
28B). Interestingly, NCX3 expression increased due to manganese exposure by 50% in Q7 but not in Q111. 
This is possibly due to manganese dependent p53 activity discussed in Chapter 2 because NCX3 has a p53 
consensus site on its promoter region, but NCX1 does not (genecards.org). 
 
 
 
Figure 28. NCX1 and NCX3 mRNA expression are diminished in Q111 cells. Quantitative RT-PCR for NCX1 (A) and 
NCX3 (B) was performed on Q7 and Q111 cells exposed to 50 µM manganese or vehicle for 24 hours. Values were 
normalized to actin expression. N = 3 for (A) and N = 6 for (B). * for p < 0.05, ** for p < 0.01, and *** for p < 0.001 by two-
way ANOVA with LSD post-hoc test. Bars = SEM.  
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formation of an NCX1-p38 complex, activating p38 to increase NCX1 expression (Xu et al., 2009). We 
hypothesized that KB-R7943 was up-regulating NCX1expression levels in Q111 to normal levels and thereby 
ameliorating the manganese-handling defect. To test this hypothesis, we performed quantitative RT-PCR on 
Q7 and Q11 cells exposed to 50 µM manganese and/or 10 µM KB-R7943 measuring NCX1 (Figure 29) 
expression. Again, we saw a severe reduction in NCX1 mRNA expression in Q111 cells regardless of 
exposure, which averaged approximately a 400 fold decrease (Figure 29A). Combined exposure of 
manganese and KB-R743 in Q7 cells led to a significant 2.3 fold increase in NCX1 mRNA expression (Figure 
29B). In Q111 cells, KB-R7943 significantly increased NCX1 mRNA expression 5-fold (Figure 29D) regardless 
of manganese exposure (Figure 29C). 
 
 
Figure 29. KB-R7943 significantly increases NCX1 expression in Q7 and Q111 cells. Quantitative RT-PCR was 
performed on Q7 and Q111 cells treated with 50 µM manganese and/or 10 µM KB-R7943. Values were normalized to 
actin expression. Data for both genotypes is presented in (A), each genotype individually in (B,C) to use different scaling, 
and Q111 in (D) without separating by manganese treatment which had no significant effect on NCX1 expression. N = 3 
independent experiments for (A-C) and N = 6 for (D).  
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Although we confirmed our hypothesis that KB-R7943 treatment was leading to an increase in NCX1 
expression, this expression change did not bring Q111 expression levels to those seen in Q7 despite 
normalization of manganese levels. One possibility is that NCX1 surface protein expression is non-existent in 
Q111 cells and our detected mRNA is either an artifact or expression is to low for significant translation into 
protein. The apparent 5 fold increase in NCX1 mRNA may be allowing NCX1 production, and over the 24 hour 
manganese exposure time, intracellular manganese levels will reach a maximal level equal to the extracellular 
concentration of manganese regardless of the exact number of NCX1 channels on the plasma membrane. 
 
Conclusions and Future Directions 
We can conclude that Q111 cells have reduced NCX1 and NCX3 expression with NCX1 expression increasing 
with KB-R7943 exposure. Future experiments are needed to measure the expression of NCX1 protein and its 
subcellular localization in Q7 and Q111 cells with and without KB-R7943 exposure. We have also generated 
expression plasmids the cloned NCX1 and NCX3 cDNA from Q7 cells. By transfecting Q111 with these genes, 
we will assess whether the manganese-handling deficit in Q111 is rescued to control levels.  
 However, these conclusions and proposed experiments would not explain the NCX1 expression deficit. 
Recently, NCX1 has been shown to be a target of the REST/NRSF transcription factor complex (Formisano et 
al., 2013), and one of the major expression alterations in Huntington’s disease is expression loss of genes 
controlled by this complex (Zuccato et al., 2003). Therefore, it is possible that NCX1 expression is decreased in 
other HD model systems as well. Alternatively, ERK and p38 have been shown to regulate expression and 
activity of the NCX proteins (Sirabella et al., 2012) . ERK1/2 signaling has been shown to be reduced in Q111 
cells due to reduced BDNF signaling and has been found to be protective against mutant huntingtin-associated 
toxicity in striatal cells (Apostol et al., 2006; Gines et al., 2003). Therefore, reduced ERK1/2 levels in 
Huntington’s disease may result in lower NCX1 levels. 
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CHAPTER V 
 
CONCLUSIONS 
 
Manganese-dependent ATM activity 
The identification of manganese responsive ATM kinase activity in an intact cellular model system is a novel 
finding. We have yet to probe the full relevance of this phenomenon, but in this discussion, I will highlight some 
of the likely possibilities. First, our finding fits well with previous literature findings (Guilarte et al., 2008). 
Namely that in non-human primate models chronically exposed to manganese have increased 
immunoreactivity for p53 and altered expression of p53 transcriptional targets (Guilarte et al., 2008). However, 
this study did not investigate the upstream kinase responsible for the increase in p53-dependent transcription. 
Importantly, manganese deficiency in the HD cells did not alter ATM activation by DNA damage. In fact, the 
manganese deplete HD cells (Q111) had elevated doubled stranded DNA break dependent ATM target 
phosphorylation, calling into question the literature claim that ATM is a manganese-dependent enzyme. This 
may not be that surprising since the original publications making this claim showed ATM becoming active when 
manganese was present regardless of the presence of DNA. Based on this literature and our findings, I 
hypothesize that ATM is activated through a novel Mn-dependent mechanism. One possible route is the 
disulfide bridge formation caused by oxidative stress shown in Guo et al 2010. In fact, this paper showed that 
high manganese concentrations (5 mM) alone can catalyze the dimerization of ATM. A 2+ redox state could 
allow manganese to potentially interact with the 2 polar sulfhydral groups that are in close proximity within the 
ATM dimer. This may catalyze the disulfide bond formation. Interestingly, the manganese specificity over other 
divalent metals suggests that whatever mechanism causes ATM activation is manganese specific. Perhaps the 
pocket near the sulfhydral groups is selective to manganese based on its distinct ionic radius.  
Interestingly, the ability of ATM to respond to manganese may constitute a manganese-sensing kinase 
that could be an important aspect of cellular manganese homeostasis. But what are the possible reasons for 
ATM to be responsive to manganese levels and the potential outcomes? It is known that p53 has a complex 
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relationship with manganese superoxide dismutase (MnSOD), one of the most highly expressed manganese 
containing enzymes. Increased p53 activity leads to a decrease in MnSOD expression, and when p53 
signaling reaches apoptotic levels, p53 translocates from the nucleus to the mitochondria where it inhibits 
MnSOD activity (Pani et al., 2000). Therefore, basally elevated p53 in HD cells could result in the increased 
sensitivity to oxidative stress seen in many model systems (Bogdanov et al., 2001; Browne & Beal, 2006; 
Polidori et al., 1999) as could decreased manganese via the same mechanism of decrease MnSOD activity 
(Chapter I). If the elevated basal p53 phosphorylation in Huntington’s disease results from a deficit in 
intracellular manganese (as Figure 25 suggests), the function of this elevation may be to decrease the 
expression of MnSOD in order to use available manganese sparingly. Therefore, the ability of ATM to respond 
to excess manganese leading to p53 phosphorylation may provide an additional layer of regulation to this 
network. 
 Another possible regulation by a manganese-sensing ATM-p53 pathway is arginase. Arginase is one of 
the most abundant manganese-dependent enzymes, and p53 is known to bind to the promoter region of the 
arginase I, ARG1 (SABiosceinces DECODE database). Although we have not published these data here, 
previous work by our group has demonstrated increased arginase activity and expression with manganese 
exposure. The ATM-p53 pathway may be an important part of arginase regulation by sensing availability of 
manganese.  
 In any case, ATM is a keep kinase balancing DNA damage, insulin, oxidative stress, and apoptotic 
signaling pathways. Even a small alteration in its biology due to reduced intracellular manganese could have 
profound effects over the lifetime of an organism. Each of these signaling pathways and processes has altered 
function in Huntington’s disease. Connecting the increased CAG repeat length in mutant Huntingtin to reduced 
manganese levels is an important direction of this research and will be discussed in the next section; however, 
it is possible that the purported interaction between ATM and mutant Huntingtin is the proximal cause for 
reduced manganese levels if ATM is a manganese sensor that can regulate manganese homeostasis 
(Ferlazzo et al., 2013). In fact, more recent experiments from the Bowman lab (not shown here) show that 
inhibition of ATM kinase activity can lead to a dramatic decrease in manganese uptake over time.  
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Mutant Huntingtin-dependent manganese deficiency 
Throughout this thesis, I have demonstrated altered manganese homeostasis seen in Huntington’s 
disease mouse striatal cells (HdhQ111/Q111). This deficit also occurred in human cells but to a lesser degree; 
however, the deficiency in manganese induced ATM kinase target phosphorylation was almost as pronounced 
as the mouse cells. Since this phosphorylation event was an outcome of intracellular manganese levels one of 
two options is possible. (1) Either the deficit is compartment specific or (2) the relationship between the level of 
ATM target phosphorylation and manganese concentration is not linear. A manganese-handling defect that is 
strongest in the nucleus (where the majority of p53, H2AX, and CHK2 are in the cell) would possibly give the 
results seen in the human cells. We have shown just such a exaggerated nuclear defect in the mouse striatal 
cell model. 
The differential extraction CFMEA provides us with an easy tool to assess intracellular manganese 
accumulation in a rapid fashion; however, it will be important to further validate what compartments each 
detergent is extracting. This can be addressed by western blot of the supernatant from the digitonin treated 
cells compared to the Triton X-100 and PBS samples with probing for compartment specific protein markers. 
Additionally, the high level of manganese in the PBS-only CFMEA needs to be addressed. This data either 
indicates a large extracellular background concentration that is not sufficiently washed away by 3 PBS washes 
or rapid efflux of manganese out of the cytoplasm. The former will call into question the exact amounts of 
manganese calculated in previous published work, and the later would provide an additional compartment 
specific assessment of intracellular manganese levels. We have yet to perform the CFMEA manganese 
quantification assay with the different detergents in the human cells, and these experiments will be critical to 
validate our finding from the mouse model. 
If the nuclear manganese localization is deficient in both human and mouse cells, this provides potential 
rational for the genomic instability and increased DNA damage and DNA damage signaling shown in this thesis 
and the literature. Indeed, the fact that manganese exposure rescues the elevated p53 in the HD mouse cells 
provides further evidence that loss nuclear manganese is the root cause. As I have already stated, it is now 
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important to assay the function of manganese dependent enzymes in the HD and control cells (both mouse 
and human) to more deeply understand the effects of manganese deficiency.  To address the genomic 
instability, manganese dependent DNA enzymes, MRE11 and DNA polymerase iota are two good candidates. 
Good immunofluorescence pattern readouts exist for MRE11 DNA damage repair but DNA polymerases 
activity is often assayed in lysates or purified protein experiments. Before these experiments, it may be good to 
assay manganese dependent enzymes that are more abundant with easily measured activity. We are currently 
assaying the activity of the manganese-dependent enzyme, arginase (Chapter I). Unpublished work from prior 
lab members has shown alterations in both expression and activity in in vivo mouse models, and the HD 
mouse striatal cells should also have a robust difference in arginase activity.  
One of the more confusing aspects of this work is the dual nature of the ATM-p53 pathway in the 
context of manganese and Huntington’s disease. In control cells, manganese exposure leads to an increase in 
ATM target phosphorylation including p53. This effect is severely diminished in HD cells and is often not 
significant in our exposure paradigm (50 µM manganese for 24 hours). On the other hand, HD cells have 
elevated p53 phosphorylation under basal conditions and in the human cells have exaggerated responses to 
DNA damaging agents. In this context, manganese exposure was actually shown to decrease p53 
phosphorylation in HD cells. I hypothesize that small amount of manganese taken up into the HD cells was not 
enough to elicit a ATM response but was enough to restore the activity of manganese dependent enzymes. In 
particular, returning proper MRE11 activity could possibily decrease MRN dependent ATM activation because 
MRN foci would be able to mature once MRE11 nuclease activity is restored. Therefore, ATM activity can be 
increased with either too little or too much manganese present.  
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Figure 30. Conceptual diagram of the relationship between intracellular manganese and p53 phosphorylation.  
 
Lastly, one of the ultimate remaining questions of this thesis work is whether the NCX1 expression 
deficit is truly the reason for the manganese accumulation deficit, and if so, does this deficiency occur in in vivo 
or human models as well? Many of the possible explanations of the effect KB-R7943 has on manganese 
uptake via NCX is through alterations to cell signaling pathways, including ERK1/2 and p38. Using the 
Pathscan assay from Chapter II, we could assess the effects of KB-R7943 exposure on a wide range of cell 
signaling pathways.  
 
Comparison of model systems 
 One unique aspect of this study was the parallel modeling of Huntington’s disease in both the murine 
striatal HdhQ7/Q7/ HdhQ111/Q111 and the human induced pluripotent stem cell derived neuroprogenitors. Each 
model system provided distinct advantages and challenges during experimentation and together they cement 
our findings in an already widely accepted disease model (Q7/Q11) and a patient-specific model (iPSCs).  
 The striatal cells (HdhQ7/Q7/ HdhQ111/Q111) are readily available through cell biorepositories 
(catalog.coriell.org). By nature, they are immortalized and in a static cell stage. This is in contrast to our iPSC-
derived neural progenitors, which are still in the process of differentiation during the experimental phase. The 
striatal cells also grow quickly as single cells that can be easily passaged by trypsinization prior to confluency. 
The iPSC-derived cultures are heterogenous containing other cells in addition the characterized “striatal-like” 
neuroprogenitors. The iPSCs take between 1-2 months from thawing a vial until experiments can be performed 
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on the differentiated neuroprogenitors. Experiments can begin in as little as 4 days after thawing the murine 
striatal cells. For these reasons, the experimental variation is also much less in the striatal cells than the iPSC-
derived cells. Therefore, the striatal cells serve greater utility when screening a large number of variables (such 
as the metals in Figure 14, while the human neuroprogenitors provide evidence that phenotypes found in the 
murine cells are artifacts of the model system and that they occur in human disease.  
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CHAPTER VI 
 
MATERIALS AND METHODS 
 
Reagents and plasmids 
The immortalized murine striatal cell line models of HD, both wild-type (STHdhQ7/Q7) and mutant 
(STHdhQ111/Q111), were obtained from Coriell Cell Repository (Cambden, NJ). The ATM kinase inhibitor, 
KU55933, was from Tocris (Bristol, UK), hydrogen peroxide was from Sigma-Aldrich (St. Louis, MO), 
neocarzinostatin was from Sigma-Aldrich (St. Louis, MO). Heavy metal cations used in this study were Cd 
(Cd2+ as CdCl2 hydrate), Cu (Cu2+ as CuSO4 pentahyrdate), Mn (Mn2+ as MnCl2 tetrahydrate), Ni (Ni2+ as NiCl2 
hexahydrate), Co (Co2+ as CoCl2 hexahydrate ), and Zn (Zn2+ as ZnCl2). Plasmids used for reprogramming (#s 
27077, 27078, and 27080) were obtained from Addgene (Cambridge, MA). 
 
Antibodies 
Antigen Species 
Clone 
name Company 
Model 
system WB ICW IF 
Islet 1 & 2 Mo 39.4D5 DSHB Hu      1:100 
Nanog Gt   R&D Systems Hu     1:20 
Oct3/4 Rb   Cell Signaling Hu      1:200 
PAX6 Rb   Covance Hu      1:100 
Pericentrin Rb   Abcam Hu     
 
1:1000 
phospho-p53(Ser15) Mo 16GB Cell Signlaing Hu, Mo  1:1000  1:400   
phospho-p53(Ser15) Rb   Cell Signaling Hu, Mo  1:1000  1:400   
p53 Mo DO-1 Santa Cruz Hu  1:1000     
p53 Rb FL-393 Santa Cruz Mo  1:1000     
phospho-H2A.X Mo JBW301 EMD Millipore Hu, Mo  1:1000  1:400   
phospho-CHK2(Thr68) Rb   Cell Signaling Hu    1:400   
SSEA3 Rt MC-631 Millipore Hu      1:500 
SSEA4 Mo MC-813-70 DSHB        1:500 
antiMouse IRDYE 800CW Dk   LI-COR   1:10,000  1:800   
antiRabbit IRDYE 800CW Dk   LI-COR      1:800   
antiRabbit IRDye 680LT Dk   LI-COR   1:10,000     
anti(mo, rb, gt, or rt) Dylight 488 or 549  Dk   Jackson        1:800 
Table 5. Antibodies. Antibodies used in this study are listed above with the species used to produce the antibody, clone 
name of all monoclonal antibodies, the company of origin, the model system that the antibody was used in, and the 
concentration used for each type of experiment. WB = western blot, ICW = In-Cell western, and IF = immunofluroescence 
microscopy. 
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Generation of human iPSC lines 
Human dermal fibroblasts were obtained from either Dr. Kevin Ess (CD, CE, CF, and HD58) or from Coriell Cell 
Repository (Cambden, NJ) (GM21756 and GM09197 which are HD70 and HD180 respectively). Primary 
dermal fibroblasts were obtained by skin biopsy from healthy adult subjects (CD, CE,  and CF) with no known 
family history of neurodegenerative disease after appropriate patient consent/assent under the guidelines of an 
approved IRB protocol (Vanderbilt #080369). Cells were grown to ~ 80% confluency, trypsinized, and counted. 
6x10^5 cells were then electroporated with the CXLE plasmid vectors using the Neon Transfection System 
(Life Technologies, Carlsbad, CA) according to the conditions described in Okita et al 2011. Cells were 
replated in normal 10% FBS medium (formulation described in “Cell Culture” section) and grown with daily 
media changes for 7 days. The cells were then trypsinized and replated at 1x10^5 cells per 100 mm dish on 
top of SNL feeder cells. The next day, the medium was changed to KOSR ES medium (described in (Neely et 
al., 2011)) and replaced daily for ~30 days before colonies were picked and propagated.  
 
Karyotype Analysis 
Human iPSC lines were submitted for standard g-band karyotype analysis by Genetics Associates, Inc., 
(Nashville, TN). For each line, 20 metaphase spreads were analyzed and normal lines used in this study has 
euploid in 20 of 20 cells. For additional experiments the number of metaphase spreads was increased to 100.  
 
Pluritest 
All iPSC lines used in this study were validated using the bioinformatics assay, “Pluritest”, developed by Muller 
F and collaborators (Müller et al., 2011). Human iPSC mRNA was isolated using the Qiagen RNeasy kit 
according to the manufacturer’s recommendations (Qiagen, Valencia, CA). Microarrays were performed by 
Expression Analysis, Inc., (Durham, NC) on Illumina Human HT-12 v4.0 expression BeadChips (Illumina, Inc., 
San Diego, CA). Pluripotency of the iPSC lines was determined by uploading binary micro-array scanner output 
files (.idat file) into the freely available Pluritest Internet application (http://www.pluritest.org).  
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Cell culture 
STHdhQ7/Q7 and STHdhQ111/Q111 immortalized murine striatal cells and human dermal fibroblasts were cultured in 
Dulbecco’s Modified Eagle Medium [D6546, Sigma-Aldrich, St. Louis MO] supplemented with 10% FBS 
[Atlanta Biologicals, Flowery Branch, GA], 2 mM GlutaMAX (Life Technologies, Carlsbad, CA), Penicillin-
Streptomycin, 0.5 mg/mL G418 Sulfate (Life Technologies, Carlsbad, CA), MEM non-essential amino acids 
solution (Life Technologies, Carlsbad, CA), 14mM HEPES (Life Technologies, Carlsbad, CA). They were 
incubated at 33°C and 5% CO2. Cells were passaged before reaching greater than 90% confluency. The cells 
were split by trypsinization using 0.05% Trypsin-EDTA solution (Life Technologies, Carlsbad, CA) incubated for 
five minutes. One day prior to exposure, cells were plated in the appropriate cell culture plate type at 8x105 
cells/mL for Q7 and 1x106 cells/mL for Q111.  
Human iPSC lines were maintained in mTeSR1 medium (StemCell technologies, Vancouver, BC) on 
Matrigel (BD Biosciences, San Jose, CA) coated 6-well plates. Media was replaced daily. Cells were passaged 
at ~50% confluency. Before passage, spontaneously differentiated cells were manually removed using a 
specific home-made glass scraper (add our book chapter reference). Then colonies were washed once in 
DMEM/F12 (Life Technologies, Carlsbad, CA) and incubated for 5-10 min with dispase (StemCell 
Technologies, Vancouver, BC). The colonies were then washed twice with DMEM/F12. The colonies were then 
scrapped into mTeSR1 and triturated several times to achieve smaller cell clump size and replated at a dilution 
of 3-5 onto Matrigel.  
 
Neural progenitor differentiation 
Human iPSC colonies grown on Matrigel in mTeSR1 were dissociated by incubating for 15 minutes in Accutase 
(Innovative Cell Technologies, San Diego, CA). Cells were diluted, centrifuged, and resuspended in mTeSR1 
medium containing 10 µM ROCK inhibitor, Y-27632 (Tocris, Bristol, UK). Cells were then replated onto Matrigel 
coated 12-well plates at a concentration of 1x10^5 cells/mL. The medium was changed 24 hours later to 
mTeSr1 without ROCK inhibitor and the cells were fed each subsequent day until cells reach > 90% confluency 
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(typically on 4 days later). Medium was then replaced with Knockout DMEM/F12 (Life Technologies, Carlsbad, 
CA) supplemented with 20% Knockout Serum Replacement (Life Tech), 2 mM Glutamax (Life Tech), MEM 
non-essential amino acids (Life Tech), and 55 µM 2-mercaptoethanol) containing 0.5 µM DMH1 (gift of Dr. 
Charles C. Hong) and 10 µM SB431542 (Tocris, Bristol, UK). After 72 hours, the medium was supplemented 
with 25% N2 medium (DMEM/F12 [with L-glutamine and HEPES] (Life Tech), 1x N2 supplement (Life Tech), 
and 4.5 g/L D-glucose) and 0.65 µM purmorphamine (Stemgent, Cambridge, MA), and SB431542 was no 
longer added. After an additional 48 hours, the N2 medium content was increased to 50%, and DMH1 was no 
longer added. After another 48 hours, an additional 25% N2 medium was added (25% neuralization medium, 
75% N2 medium). Cultures were dissociated 10 days after the initial addition of neuralization medium via a 20 
minute incubation with Accutase. For all experiments using human iPS-derived neural progenitors, cells were 
replated onto Matrigel-coated dishes at 7x105 cells/mL in 100% N2 medium containing 0.65 µM 
purmorphamine and 10 µM ROCK inhibitor, Y-27632. The next day the experimental exposure was added in 
100% N2 medium containing purmorphamine without ROCK inhibitor. Assays were performed 24 hours later. 
 
CellTiterBlue Cytotoxicity Assay 
Human neural progenitors or mouse striatal cells (STHdhQ7/Q7, STHdhQ111/Q111) were grown on 96-well plates. 
The day after replating, they were exposed to toxicants in the cell type appropriate neuralization medium. At 2 
hours prior to the completion of the 24-hour exposure period or after toxicant removal and washes following 1-
hour exposures, 20 µL of CellTiterBlue reagent (Promega, Madison, WI) was added to each well. Prior to this 
addition, cell lysis buffer was added to several wells to provide an accurate fluorescence background for 0% 
viable cells. The plates were then incubated for 2 hours at 37° C. Fluorescence was measured using excitation 
of 570 nm and emission of 600 nm on a POLARstar Omega microplate reader (BMG Labtech, Ortenberg, 
Germany).  
 
MTT Assay 
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For the neocarzinostatin treatment viability assay, induced pluripotent stem cells were plated at 100,000 
cells/mL in mTeSR1 with Rho-kinase inhibitor, Y-27632 (Tocris, Bristol, UK). Cells were exposed to 
neocarzinostatin in mTeSR1 for 1 hour followed by washing twice in PBS and replacing with fresh mTesr1 
medium. Cells were then placed back in the incubator for an additional 23 hours. MTT, (3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide, was added to each well for a final concentration of 0.5 % MTT. After 2 
hours of incubation, the medium was removed and cells with formazan crystal were dissolved in a solution of 
10% Sorenson’s buffer in 90% DMSO. Absorbance readings were taken at 570-590 nm. 
 
Cellular Fura-2 Manganese Extraction Assay (CFMEA) 
 CFMEA was performed exactly as described previously (K. K. Kumar et al., 2013). In short, cells grown in 96-
well plates were exposed to either 50 µM MnCl2 in cell culture medium for 24 hours or 125 µM MnCl2 for 3 
hours in Hank’s buffered salt solution (HBSS). The wells were then washed 3 times with PBS. PBS was then 
added containing 0.75 µM Fura-2 , 0.1% Triton X-100, and Alexa Fluor 568 (dextran conjugate). Cells were 
incubated at room temperature in the dark for > 20 min. Fura-2 fluorescence was measure on a Beckman-
Coulter DTX 880 multimode plate reader excitation/emission 360/535 nM. Manganese concentration was 
calculated based on a manganese-dependent quenching curve of Fura-2 fluorescence. Alexa Fluor 568 
fluorescence was used as a volumetric control. Matrigel-coated wells show a manganese concentration 
dependent background that is not observed in uncoated wells. A manganese concentration-specific 
background was therefore subtracted from the experimental signals of wells containing matrigel. Manganese 
content was normalized to DNA content of each culture unless otherwise specified. This was performed by the 
Quant-iT PicoGreen dsDNA Assay kit.  
 
DNA Polymerase Chain Reaction (PCR) 
PCR was performed for both validation of the loss of the episomal plasmid vector and for validating the HD 
mutation in the iPSC lines. DNA was isolated using the DNeasy kit (Qiagen, Valencia, CA) and quantified using 
a Nanodrop 1000 spectrophotometer (Nanodrop Instruments). Primers and template DNA were mixed with 
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GoTaq Green 2X Master Mix (Promega, Madison, WI). The PCR amplification was performed on a MyCycler 
Thermal Cycler (Bio-Rad, Hercules, CA). For amplification of the mutant Huntingtin gene CAG repeat region, 
1X Q buffer (Qiagen, Valencia, CA) and 5% DMSO were added. DNA products were run on 1 or 2% agarose 
gels in TBE buffer and stained with ethidium bromide.  
 
Quantitative Reverse Transcriptase PCR 
Cells were lysed using RLT buffer with 1% BME and homogenized on QIAshredder columns (Qiagen, 
Valencia, CA). Total RNA was isolated using the RNeasy kit with on column RNase-free DNase treatment 
(Qiagen, Valencia, CA). Total RNA was quantified using a Nanodrop 1000 spectrophotometer (Thermo 
Scientific, Waltham, MA). First strand cDNA synthesis reactions were performed on 1 µg of total RNA using the 
SuperScript III kit with random hexamers (Life Technologies, Carlsbad, CA). Quantitative PCR was performed 
using the Power SYBR Green Master Mix (Life Technologies, Carlsbad, CA) as 10 µL reactions in 384-well 
plates with 10 ng of cDNA on a 7900HT fast real-time PCR system (Applied Biosystems, Carlsbad, CA). 
Primers are listed in Table 4. Actin was used as a normalizing control gene. 
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Primer Name Gene Sequence Tm Product Size 
AT83 FOXG1 F CAACGGCATCTACGAGTTCA 59.9 57 
AT84 FOXG1 R TGCTTGTTCTCGCGGTAGTA 59.7   
AT95 PAX6 F CAGCTTCACCATGGCAAATA 59.7 77 
AT96 PAX6 R GCAGCATGCAGGAGTATGAG 59.6   
AT103 Actin F CTGTGGCATCCACGAAACTA 59.7 84 
AT104 Actin R AGCACTGTGTTGGCGTACAG 60.0   
AT277 Islet-1 F ACGGTGGCTTACAGGCTAAC 59.3 56 
AT278 Islet-1 R TTTCCAAGGTGGCTGGTAAC 60.0   
1594 HTT CAG Repeat F CCGCTCAGGTTCTGCTTTTA 60.5 278 
1595 HTT CAG Repeat R GGCTGAGGAAGCTGAGGAG 60.2 (19 CAG repeats) 
Insertion1 WPRE F CAGGCAACGTGGCGTGGTGT  70.0 265 
Insertion2 WPRE R GGACGTCCCGCGCAGAATCC 71.5   
AT335 Mouse Actin F CAGCCTTCCTTCTTGGGTAT 58.3 83 
AT336 Mouse Actin R CGGATGTCAACGTCACACTT 59.6   
AT327 Mouse p21 F GAGGCCCAGTACTTCCTCTG 58.9 78 
AT328 Mouse p21 R AGAGTGCAAGACAGCGACAA 59.8   
AT321 Mouse NCX1 CGACTTGAGCACCACTGTGT 59.9 108 
AT322 Mouse NCX1 TCCCCTGGTTTGAAGATCAC 59.9   
AT323 Mouse NCX2 TCAACCAAGGGAATGGAGAC 59.9 75 
AT324 Mouse NCX2 GCTTGCCCATCTCTGCTATC 59.9   
AT325 Mouse NCX3 CCCATGTTCCTGCTTGTTTT 60 115 
AT326 Mouse NCX3 CCTGGATTCTTTGGCAATGT 59.9   
 
Table 4. Primer sequences for PCR and quantitative reverse transcriptase PCR. Identifying numbers were assigned 
to each new primer designed for human and mouse (where noted) genes listed. The melt temperature was calculated via 
the Breslauer et al 1986 table of thermodynamic properties and the Schildkraut and Lifson 1965 salt correction formula. 
Expected product sizes are from a mRNA library not necessarily genomic DNA because some primer sets span exon-
intron boundaries. 
 
PathScan ELISA Array 
The assay was performed following the manufacturers instructions. In brief, cells were washed once with ice-
cold PBS and lysed with ice-cold sandwich ELISA array lysis buffer (Cell Signaling, Danvers, MA) containing 1 
mM PMSF for 5 minutes on ice. The lysates were then pipetted into pre-chilled tubes. Lysate protein 
concentration was calculated using the DC protein assay (Promega, Madison, WI). After diluting to equivalent 
concentrations, lysates were added to the prepared PathScan Intracellular signaling array (Cell Signaling, 
Danvers, MA). The fluorescent signal was assessed using the Odyssey Infrared Imaging system (LI-COR, 
Lincoln, NE). Two wells were incubated in dilution buffer only and provided the background signal for each 
pathway. Only signal intensities ≥ 3 fold the background signal are reported, except for cleavage of caspase-3 
and PARP-1. Since human data was generated on a single slide, the data was divided by the mean of the 
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untreated sample intensities to achieve a fold change value. For the mouse PathScan, each of the three data 
points for each signaling pathway were generated on a separate slide on separate days. Therefore, the values 
for each day were divided by the untreated sample intensity for that day. Therefore, the untreated means have 
no variance since all values are 1. 95% confidence intervals were used to calculate statistical significance. 
Human cell analysis was performed by t test.  
 
Immunoblot analysis 
Protein samples were prepared by scraping cells into ice-cold PBS, centrifuging, and adding RIPA buffer 
containing protease (Sigma-Aldrich, St. Louis, MO) and phosphatase inhibitor cocktails 2 & 3 (Sigma, Sigma-
Aldrich, St. Louis, MO) to the pellet. After gentle homogenization, cells were centrifuged at 4 C for 10 minutes 
at 20,000 g. The resulting DNA containing pellet was removed from the lysate, and the protein concentration 
was quantified using the DC assay (BioRad, Hercules, CA) with a BSA standard curve. Samples were mixed 
with 5x SDS loading buffer containing 1% 2-mercaptoethanol and boiled for 5 minutes. 15 µg of protein was 
loaded for each sample onto a 4-15% pre-cast gel SDS-PAGE gel (BioRad, Hercules, CA) and run at 90V for 
120 minutes. The protein bands were then transferred onto nitrocellulose membranes using iBlot Gel Transfer 
Device (Life Technologies), and the protein was transferred onto a nitrocellulose membrane. The remaining gel 
was stained with IRDye Blue protein stain (LI-COR, Lincoln, NE). Since the gels retained ~1/3 of the original 
protein after transferring with the iBlot, we imaged the stained gel on the Li-Cor Odyssey Imaging System and 
quantified the intensity entire lane from ~150-20 kDa. This value was used to normalize the values of 
immunostained bands. The membrane was blocked in Odyssey Blocking Buffer for one hour prior to the 
addition of the primary antibodies. The primary antibodies were diluted in Odyssey Blocking Buffer containing 
0.1% TWEEN and incubated overnight. After washing 5 times for 5 minutes in TBST, membranes were 
incubated with secondary antibodies at 1:10,000 (LiCor, Lincoln, NE) for 1 hour. Membranes were imaged 
using the Li-Cor Odyssey Imaging System, and quantification was performed using Image Studio Lite (LiCOR, 
Lincoln, NE). 
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In-Cell Western Assay 
Cells were plated in 96-well µClear black-walled plates (Greiner Bio-One, Frickenhausen, Germany) at the 
appropriate density for the particular line. After exposing cells to toxicants, they were washed once in room 
temperature PBS (without calcium and magnesium). The cells were then fixed with 4% paraformaldehyde in 
PBS for 30 minutes at room temperature, washed 5 times for in PBS with 0.1% Triton-X 100, and blocked for 
1.5 hours in 150 µL of Odyssey blocking buffer. The cells were then incubated with primary antibody at 1:400 
in Odyssey blocking buffer (LiCor, Lincoln, NE) with 50 µL in each well for 2.5 hours. After washing 4 times in 
PBS with 0.1% Tween-20 for 5 minutes, cells were incubated for 1 hour in the appropriate LiCor IRdye800 
secondary antibody at 1:800 dilution in Odyssey blocking buffer along with 1:500 of CellTag normalization dye 
(LI-COR, Lincoln, NE). An additional round of 5 washes for 5 minutes in PBS with Tween-20 was performed 
after which all buffer was removed. Plates were imaged with the Li-Cor Odyssey Imaging System and 
intensities were calculated for each well with Image Studio software. Cultures that were no incubated with 
primary antibodies served as backgound. Antibody signals were normalized using the  CellTag signal (a 
measure of total cells). We have included exemplary images from both human and In-Cell Western assays in 
the appendix. 
 
Immunofluorescence microscopy 
Cells were fixed in paraformaldehyde for 30 min at room temperature. After permeabilization with 0.2% Triton-
X100 for 20 min at room temperature, cells were incubated in PBS containing 5% donkey serum and 0.05% 
Triton-X100 for 2 h at room temperature or overnight. Cell were incubated in primary antibody overnight (see 
table to antibody dilutions), washed in PBS with 0.05% Triton-X100 and incubated for 3 hours with secondary 
antibody. Images were obtained with a Zeiss ObserverZ1 microscope and AxioVs40 software (version 4.7.2).  
 
Centrosome counting 
Fibroblasts and iPS cells were grown on Nunc Lab-Tek I Chamber slides (Thermo Scientific,). Cells were 
immunostained for immunofluorescence microscopy as described above for pericentrin (Abcam, 1:1000). 
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Coverslips were mounted over the cells using Prolong Gold Antifade Reagent with DAPI (Life Technologies). 
Using a Zeiss ObserverZ1 microscope, cells undergoing mitosis were identified by loss of nuclear envelope 
and distinct chromosome morphology. While blinded to genotype, these cells were then scored for the number 
of centrosomes by focusing up and down in the channel stained by the pericentrin antibody. Cells with 1 or 2 
distinct centrosomes were scored as normal, while those with 3 or more were counted as abnormal. Each line 
in each experiment had 20 cells scored.  
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APPENDIX 
 
In-Cell Western Images 
Appendix Figure 1. Image of In-Cell Western assays for ATM targets in CF-3 and HD70-2 human 
neuroprogenitors. Human neuroprogenitors plated onto 96-well plates were exposed for 24 hours to manganese (50 
µM), 1 hour neocarzinostatin (100 ng/mL), and/or KU-55933 (1 µM). The In-Cell Western assay was then used to quantify 
the expression of several phosphorylation events as list above the figure. Columns of wells labeled as (Ab-) did not 
receive a primary antibody and served as a background/non-specific binding control, for the columns of wells labeled as 
(Ab+). 
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Appendix Figure 2. Image of In-Cell Western assay for phospho-p53(S15)(mo). Mouse STHdh neuroprogentiors 
plated onto 96-well plates were exposed for 24 hours to manganese (50 µM), 1 hour neocarzinostatin (100 ng/mL), or 1 
hour H2O2 (250 µM). The In-Cell Western assay was then performed to quantify the expression of several phosphorylation 
events as list above the figure. Columns labeled (Ab-) did not receive a primary antibody and served as a 
background/non-specific binding control for the other wells. 
 
 
 
 
 
 
 
 
 
STHdhQ7/Q7# STHdhQ111/Q111#
##Ab&# #Ab&#
Veh#
Mn##10#µM#
Mn##50#µM#
NCS#
NCS#+#Mn#
H2O2#100#µM#
H2O2#250#µM#
H2O2#250#µM#
#+#Mn#
In&Cell#Western#assay#for#phosS15&p53#(mo)##
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